Strain Name:


Stock Number:


Order this mouse


Repository- Live

Use Restrictions Apply, see Terms of Use
This KrasLSL-G12D strain carries a Lox-Stop-Lox (LSL) termination sequence with the K-ras G12D point mutation. When bred to a strain expressing Cre recombinase under control of various tissue specific promoters, Cre recombination deletes the transcriptional termination sequence and allows the expression of the oncogenic protein. There is a phenotypic similarity to the Intrahepatic Cholangiocarcinoma and Granulosa Cell Tumor syndromes in humans. This strain may be useful in studies of cancer and development.


Strain Information

Former Names B6.129S4-Krastm4Tyj/J    (Changed: 02-APR-08 )
Type Congenic; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Mating System+/+ sibling x Heterozygote         (Female x Male)   21-NOV-08
Specieslaboratory mouse
GenerationN11+N1F11 (16-DEC-13)
Generation Definitions
Donating InvestigatorDr. Tyler Jacks,   Massachusetts Institute of Technology

This KrasLSL-G12D strain carries a point mutation (G12D) whose expression is blocked by the presence of a loxP-flanked stop codon. Homozygotes die in utero. Cre-mediated recombination can excise the stop codon and permit the oncogenic protein to be expressed. Intranasal infection with an adenovirus encoding Cre results in a very high frequency of lung tumors and permits controlled timing of tumor initiation and tumor multiplicity. This strain may be useful in studies of cancer and development.

When bred to a strain expressing Cre recombinase under the control of a tetracycline-responsive promoter element and a strain expressing a tetracycline-controlled activator protein in lung epithelial cells (see Stock No. 006234 and 006235 respectively), this mutant mouse strain may be useful in studies of lung development.

When bred to a strain expressing Cre recombinase in the male germ line (see Stock No. 003328, 007252 for example), this mutant mouse strain may be useful in studies of embryonic development.

When bred to a strain expressing interferon inducible Cre recombinase (see Stock No. 003556, 005673 for example), this mutant mouse strain may be useful in studies of Ras and myeloproliferative disease.

When bred to a strain expressing Cre recombinase in mammary gland, skin, and other secretory glands (see Stock No. 003553 for example), this mutant mouse strain may be useful in studies of epithelial hyperplasias.

When bred to a strain expressing Cre recombinase in epiblast derived tissues (see Stock No. 003755 for example), this mutant mouse strain may be useful in studies of Ras and embryonic development.

When bred to a strain expressing Cre recombinase in liver (see Stock No. 003574 for example), this mutant mouse strain may be useful in studies of intrahepatic cholangiocarcinoma.

When bred to a strain expressing Cre recombinase in myeloid cell lineage (see Stock No. 004781 for example), this mutant mouse strain may be useful in studies of lung cancer.

When bred to a strain expressing tamoxifen-inducible Cre recombinase in melanocytes (see Stock No. 012328 for example), this mutant mouse strain may be useful in studies of melanomagenesis.

When bred to a strain expressing Cre recombinase in astrocytes (see Stock No. 012887 for example), this mutant mouse strain may be useful in studies of neurofibroma development.

A targeting vector was designed to place a G12D point mutation in exon 1 of the gene and a loxP-flanked STOP element upstream of the mutation. The STOP element incorporates a PGK-puromycin selection cassette at the 5' end in an opposite directional orientation. An adenoviral strong splice acceptor, typically used in gene trap vectors, is fused upstream of the his3 stuffer fragment to prevent splicing around the stopper (in the case that transcription isn't completely silenced). A mutant splice donor site is on the 3' end and a tetrameric tandem array of SV40 PolyA. The stopper was designed to fit into genomic Sal1 or Xho1 sites. The stop cassette prevents the expression of mutant Kras until it is removed by Cre mediated recombination of the Loxp sites, thus allowing expression of oncogenic Kras. The construct was electroporated into 129S4/SvJae-derived J1 embryonic stem (ES) cells. This strain was backcrossed to C57BL/6 for more than 10 generations by the donating laboratory which verified correct orientation by Southern assays involving 5' and 3' external and internal probes.

Control Information

   Wild-type from the colony
   000664 C57BL/6J
  Considerations for Choosing Controls

Related Strains

Strains carrying   Krastm4Tyj allele
008180   129S/Sv-Krastm4Tyj/J
019104   B6N.Cg-Krastm4Tyj/CjDswJ
View Strains carrying   Krastm4Tyj     (2 strains)

Strains carrying other alleles of Kras
002674   129-Krastm1Tyj/J
008185   129S/Sv-Krastm3Tyj/J
023590   B6(Cg)-Krastm5Tyj/J
008653   B6;129-Krastm5Tyj/J
View Strains carrying other alleles of Kras     (4 strains)

Additional Web Information

Introduction to Cre-lox technology


Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Model with phenotypic similarity to human disease where etiologies involve orthologs. Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).
Lung Cancer
Models with phenotypic similarity to human diseases where etiology is unknown or involving genes where ortholog is unknown.
Endometriosis, Susceptibility to, 1
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
Bladder Cancer   (KRAS)
Breast Cancer   (KRAS)
Cardiofaciocutaneous Syndrome 2; CFC2   (KRAS)
Gastric Cancer, Hereditary Diffuse; HDGC   (KRAS)
Noonan Syndrome 3; NS3   (KRAS)
Pancreatic Cancer   (KRAS)
Schimmelpenning-Feuerstein-Mims Syndrome; SFM   (KRAS)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype


        B6.129S4-Krastm4Tyj   (conditional)
  • mortality/aging
  • premature death
    • mutants with an intranasal instillation of an adenovirus expressing Cre recombinase have a median survival of 79 days   (MGI Ref ID J:177379)
  • tumorigenesis
  • increased lung adenocarcinoma incidence
    • mutants with an intranasal instillation of an adenovirus expressing Cre recombinase develop noninvasive adenoma and adenocarcinoma over a 6-10 week period, characterized by epithelial cell proliferation without destruction of alveolar walls or stromal reaction   (MGI Ref ID J:177379)
  • increased lung adenoma incidence
    • mutants with an intranasal instillation of an adenovirus expressing Cre recombinase develop noninvasive adenoma and adenocarcinoma over a 6-10 week period, characterized by epithelial cell proliferation without destruction of alveolar walls or stromal reaction   (MGI Ref ID J:177379)


        B6.129S4-Krastm4Tyj   (conditional)
  • cellular phenotype
  • increased cell proliferation
    • primary mouse embryonic fibroblast treated with adenoviral-cre exhibit enhanced growth rate compared with wild-type cells   (MGI Ref ID J:187371)

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.


        involves: 129S4/SvJae
  • tumorigenesis
  • increased lung tumor incidence
    • treatment with adenoviral Cre to induce oncogenic Kras expression results in lung tumor development, but causes a lower tumor burden and decreased overall tumor area compared to induced mutants on a Spry2-null background   (MGI Ref ID J:119477)
    • increased lung adenocarcinoma incidence
      • a few adenocarcinomas develop in mice following Ad-Cre administration   (MGI Ref ID J:207982)
    • increased lung adenoma incidence
      • mice develop lung adenomas with a few adenocarcinomas following intratracheal administration of an adenovirus expressing Cre (Ad-Cre)   (MGI Ref ID J:207982)
      • treatment with MLN4924, a small molecular inhibitor of NAE, beginning at 13 weeks after Ad-Cre administration reduces tumor burden, with a reduction in both number of hyperplastic areas and adenomas and size of the tumors   (MGI Ref ID J:207982)


        involves: 129S4/SvJae   (conditional)
  • mortality/aging
  • premature death
    • median life span of cre adenovirus-treated mice is 32 weeks   (MGI Ref ID J:147590)
  • tumorigenesis
  • altered tumor morphology
    • tumors from cre adenovirus-treated mice exhibit increased cell proliferation compared to in tumors from Krastm4Tyj/Kras+ Rbl2tm2Tyj/Rbl2tm2Tyj mice   (MGI Ref ID J:147590)
    • decreased tumor growth/size
      • cre adenovirus-treated mice develop smaller tumors than in cre adenovirus-treated Krastm4Tyj/Kras+ Rbl2tm2Tyj/Rbl2tm2Tyj mice   (MGI Ref ID J:147590)
  • increased lung tumor incidence
    • mice treated with adenovirus cre develop lung lesions in 4 to 6 months   (MGI Ref ID J:147590)
    • cre adenovirus-treated mice develop lung adenocarcinomas, papillary adenomas and bronchiolar hyperplasia and dysplasia   (MGI Ref ID J:147590)
    • cre adenovirus-treated mice develop fewer tumors than in Krastm4Tyj/Kras+ Rb1tm3Tyj/Rb1tm3Tyj mice   (MGI Ref ID J:147590)
    • large tumors easily visible on the surface of the lungs at eight weeks after Cre-adenovirus treatment   (MGI Ref ID J:158937)
    • increased lung adenoma incidence
      • presence of atypical adenomatous hyperplasia after Cre-adenovirus treatment   (MGI Ref ID J:158937)
    • increased lung carcinoma incidence
      • the most common lesion is adenocarcinoma after Cre-adenovirus treatment   (MGI Ref ID J:158937)
      • increased lung adenocarcinoma incidence
        • in cre adenovirus-treated mice   (MGI Ref ID J:147590)
  • respiratory system phenotype
  • abnormal bronchiole morphology
    • cre adenovirus-treated mice develop bronchiolar hyperplasia and dysplasia unlike wild-type mice   (MGI Ref ID J:147590)
    • bronchiolar epithelial hyperplasia
      • in cre adenovirus-treated mice   (MGI Ref ID J:147590)
  • lung epithelium hyperplasia
    • presence of epithelial hyperplasia after Cre-adenovirus treatment   (MGI Ref ID J:158937)
  • thick pulmonary interalveolar septum
    • in cre adenovirus-treated mice   (MGI Ref ID J:147590)
  • immune system phenotype
  • increased regulatory T cell number
    • following injection of a cre adenovirus in the ovarian bursa, mice with endometriosis also exhibit an increase in spleen and regional lymph nodes T regulatory cells compared with un-injected Krastm4Tyj Tg(MUC1)79.24Gend mice   (MGI Ref ID J:154046)
  • hematopoietic system phenotype
  • increased regulatory T cell number
    • following injection of a cre adenovirus in the ovarian bursa, mice with endometriosis also exhibit an increase in spleen and regional lymph nodes T regulatory cells compared with un-injected Krastm4Tyj Tg(MUC1)79.24Gend mice   (MGI Ref ID J:154046)
  • reproductive system phenotype
  • uterus adenomyosis
    • following injection of a cre adenovirus in the ovarian bursa, mice develop ovarian lesions consisting of endometrial glandular epithelium unlike un-injected Krastm4Tyj micefollowing injection of a cre adenovirus in the ovarian bursa, mice develop ovarian lesions consisting of endometrial glandular epithelium unlike un-injected Krastm4Tyj mice   (MGI Ref ID J:154046)


        either: (involves: 129S4/SvJae) or (involves: 129S4/SvJae * C3H/HeJ)   (conditional)
  • endocrine/exocrine gland phenotype
  • abnormal ovary morphology
    • after ovarian intrabursal injection of an adenovirus expressing Cre, mutants develop benign ovarian endometriosis-like lesions, however no invasive ovarian tumors are seen up to 10 months following adenoviral injection   (MGI Ref ID J:96296)
  • growth/size/body phenotype
  • abnormal peritoneum morphology
    • 47% of mutants develop peritoneal endometriosis following ovarian intrabursal injection of an adenovirus expressing Cre   (MGI Ref ID J:96296)
    • however, mice injected with adenovirus expressing Cre directly into the peritoneum do not develop peritoneal endometriosis   (MGI Ref ID J:96296)
  • reproductive system phenotype
  • abnormal ovary morphology
    • after ovarian intrabursal injection of an adenovirus expressing Cre, mutants develop benign ovarian endometriosis-like lesions, however no invasive ovarian tumors are seen up to 10 months following adenoviral injection   (MGI Ref ID J:96296)


        involves: 129S4/SvJae * C57BL/6   (conditional)
  • tumorigenesis
  • increased lung adenoma incidence
    • lung adenocarcinomas cover 11% of lung area 9 weeks after administration of a Cre-recombinase expressing adenovirus   (MGI Ref ID J:203686)

The following phenotype relates to a compound genotype created using this strain.
Contact JAX® Services for customized breeding options.

Krastm4Tyj/Kras+ Lyz2tm1(cre)Ifo/Lyz2+

        involves: 129P2/OlaHsd * 129S4/SvJae   (conditional)
  • mortality/aging
  • complete postnatal lethality
    • the maximum survival is 24 days   (MGI Ref ID J:158937)
  • respiratory system phenotype
  • increased lung weight
    • lung weight is 10-fold higher than that in control mice at 3 weeks old   (MGI Ref ID J:158937)
  • tumorigenesis
  • increased lung tumor incidence   (MGI Ref ID J:158937)

Krastm4Tyj/Kras+ Tg(Alb-cre)21Mgn/0

        involves: 129S4/SvJae * C57BL/6 * DBA   (conditional)
  • tumorigenesis
  • increased cholangiocarcinoma incidence
    • mutants develop invasive intrahepatic cholangiocarcinoma with low penetrance (1 of 8 mutants) and long latency (at 36 weeks of age)   (MGI Ref ID J:184949)

Krastm4Tyj/Kras+ Tg(Gfap-cre)77.6Mvs/0

        involves: 129 * BALB/c * C57BL/6NHsd   (conditional)
  • tumorigenesis
  • *normal* tumorigenesis
    • mutants do not develop tumors   (MGI Ref ID J:154673)

Krastm4Tyj/Kras+ Tg(Krt1-15-cre/PGR)22Cot/0

        involves: 129S4/SvJae * C57BL/6 * SJL   (conditional)
  • tumorigenesis
  • increased facial tumor incidence
    • 2-4 months following RU486 treatment, tumors develop in the face in 35% of treated mutants   (MGI Ref ID J:172048)
    • increased lip tumor incidence
      • 2-4 months following RU486 treatment, lip tumors develop in 57% of treated mice   (MGI Ref ID J:172048)
  • increased skin tumor incidence
    • 2-4 months following RU486 treatment, tumors develop in the back skin in 14% of treated mice   (MGI Ref ID J:172048)
    • increased skin papilloma incidence
      • skin tumors are benign papillomas with no sign of malignant transformtion seen up to 4 months after treatment with RU486   (MGI Ref ID J:172048)
      • double mutants not treated with tamoxifen develop some papillomas but with increased latency (>6 months)   (MGI Ref ID J:172048)
  • integument phenotype
  • increased skin tumor incidence
    • 2-4 months following RU486 treatment, tumors develop in the back skin in 14% of treated mice   (MGI Ref ID J:172048)
    • increased skin papilloma incidence
      • skin tumors are benign papillomas with no sign of malignant transformtion seen up to 4 months after treatment with RU486   (MGI Ref ID J:172048)
      • double mutants not treated with tamoxifen develop some papillomas but with increased latency (>6 months)   (MGI Ref ID J:172048)

Krastm4Tyj/Kras+ Tg(Krt1-15-cre/PGR)22Cot/0

        involves: 129S4/SvJae * C57BL/6 * C57BL/6J * SJL/J   (conditional)
  • tumorigenesis
  • increased papilloma incidence
    • mice develop benign papillomas without progressing to malignancy following topical application of RU486 to the back of skin at 3 weeks of age for 5 days   (MGI Ref ID J:203922)

Krastm4Tyj/Kras+ Tg(MMTV-cre)4Mam/0

        involves: 129S4/SvJae * FVB   (conditional)
  • endocrine/exocrine gland phenotype
  • submandibular gland hyperplasia
    • submandibular gland hyperplasia is seen in mutant mice   (MGI Ref ID J:89333)
  • digestive/alimentary phenotype
  • submandibular gland hyperplasia
    • submandibular gland hyperplasia is seen in mutant mice   (MGI Ref ID J:89333)

Krastm4Tyj/Kras+ Tg(Mx1-cre)1Cgn/?

        involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA   (conditional)
  • mortality/aging
  • premature death
    • survival for around 35 days after pI-pC treatment   (MGI Ref ID J:88163)
    • survival of around 58 days even without pI-pC treatment   (MGI Ref ID J:88163)
  • tumorigenesis
  • increased T cell derived lymphoma incidence
    • thymic T-cell lymphomas   (MGI Ref ID J:88163)
  • increased lung adenoma incidence
    • nodules in lungs   (MGI Ref ID J:88163)
  • increased papilloma incidence
    • squamous papillomas   (MGI Ref ID J:88163)
  • growth/size/body phenotype
  • cachexia
    • becoming emaciated   (MGI Ref ID J:88163)
  • hematopoietic system phenotype
  • abnormal hematopoiesis
    • develop lethal hematopoietic disease   (MGI Ref ID J:88163)
    • abnormal erythrocyte morphology   (MGI Ref ID J:88163)
      • decreased hematocrit
        • average hematocrit of 27%   (MGI Ref ID J:88163)
    • extramedullary hematopoiesis
      • expansion of red pulp in spleen by granulocyte/monocyte lineages in 11 out of 16 cases   (MGI Ref ID J:88163)
      • erythroid expansion was seen in red pulp of spleen in 5 of 16 cases   (MGI Ref ID J:88163)
    • increased leukocyte cell number
      • leukocytosis, usually involving increases in granulocytes   (MGI Ref ID J:88163)
    • myeloid hyperplasia
      • myeloproliferative phenotype   (MGI Ref ID J:88163)
      • myeloid hyperplasia of bone marrow   (MGI Ref ID J:88163)
  • immune system phenotype
  • increased leukocyte cell number
    • leukocytosis, usually involving increases in granulocytes   (MGI Ref ID J:88163)
  • myeloid hyperplasia
    • myeloproliferative phenotype   (MGI Ref ID J:88163)
    • myeloid hyperplasia of bone marrow   (MGI Ref ID J:88163)
  • liver/biliary system phenotype
  • abnormal hepatobiliary system morphology
    • perivascular and periportal infiltration in liver by myeloid and erythroid cells similar to what is seen in spleen   (MGI Ref ID J:88163)
  • integument phenotype
  • ruffled hair
    • ruffled fur   (MGI Ref ID J:88163)

Krastm4Tyj/Kras+ Tg(Tyr-cre/ERT2)13Bos/0

        involves: 129S4/SvJae * FVB   (conditional)
  • tumorigenesis
  • increased melanoma incidence
    • 1 in 14 tamoxifen treated mice develops melanoma with a median tumor latency greater than 52 weeks   (MGI Ref ID J:164588)
  • pigmentation phenotype
  • abnormal melanocyte morphology
    • tamoxifen-treated mice exhibit melanocytic proliferation unlike wild-type mice   (MGI Ref ID J:164588)
  • hyperpigmentation
    • tamoxifen-treated mice develop pigmented macules in the paws and tail unlike wild-type mice   (MGI Ref ID J:164588)

Krastm4Tyj/Krastm4Tyj Tg(Prm-cre)58Og/0

        involves: 129S4/SvJae   (conditional)
  • mortality/aging
  • complete embryonic lethality during organogenesis
    • mutants die between E9.5 and 11.5   (MGI Ref ID J:119477)
  • embryogenesis phenotype
  • abnormal placenta labyrinth morphology
    • marked defect in inner labyrinth layer is observed at E9.5   (MGI Ref ID J:119477)
    • abnormal placental labyrinth vasculature morphology
      • fetal blood vessels underlying inner labyrinth layer are absent   (MGI Ref ID J:119477)
  • absent vitelline blood vessels
    • at E9.5 vasculature is poorly developed; vasculature has a primitive honeycomb-like network lacking branching vitelline vessels, while large vitelline vessels are absent   (MGI Ref ID J:119477)
  • embryonic growth arrest
    • embryos show developmental arrest   (MGI Ref ID J:119477)
  • pale yolk sac
    • at E9.5, yolk sacs are pale and roughened   (MGI Ref ID J:119477)
  • cellular phenotype
  • increased apoptosis
    • at death, embryos exhibit widespread apoptosis   (MGI Ref ID J:119477)
  • cardiovascular system phenotype
  • abnormal placental labyrinth vasculature morphology
    • fetal blood vessels underlying inner labyrinth layer are absent   (MGI Ref ID J:119477)
  • absent vitelline blood vessels
    • at E9.5 vasculature is poorly developed; vasculature has a primitive honeycomb-like network lacking branching vitelline vessels, while large vitelline vessels are absent   (MGI Ref ID J:119477)

Krastm4Tyj/Krastm4Tyj Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-cre)1Jaw/0

        involves: 129/Sv * C57BL/6   (conditional)
  • mortality/aging
  • complete postnatal lethality
    • death in the early postnatal period   (MGI Ref ID J:119477)
  • respiratory system phenotype
  • abnormal branching involved in lung morphogenesis
    • with doxycycline treatment beginning at E6.5, a dramatic lung branching defect is observed   (MGI Ref ID J:119477)
    • at E16.5, lungs show even more severe defects than in Kras:Meox2-cre embryos, with large epithelial-lined pouches in place of finely branched network of airways seen in wild-type   (MGI Ref ID J:119477)
    • branching defect persists through late gestation leading to early postnatal lethality   (MGI Ref ID J:119477)
  • abnormal lung epithelium morphology
    • branching defect originates in epithelium rather than mesenchyme   (MGI Ref ID J:119477)
    • abnormal bronchus epithelium morphology
      • markers of ciliated and Clara cells in the bronchi are significantly reduced at E18.5 compared to controls, indicating block in differentiation of lung epithelium   (MGI Ref ID J:119477)

Krastm4Tyj/Krastm4Tyj Tg(Tek-cre)12Flv/0

        involves: 129S4/SvJae * C3H * C57BL/6   (conditional)
  • embryogenesis phenotype
  • *normal* embryogenesis phenotype
    • mutants show normal vascularization of the yolk sac and placental labyrinth   (MGI Ref ID J:119477)

Krastm4Tyj/Kras+ Meox2tm1(cre)Sor/Meox2+

        involves: 129S4/SvJae * 129S4/SvJaeSor   (conditional)
  • mortality/aging
  • complete lethality throughout fetal growth and development
    • homozygous embryos die by E14.5   (MGI Ref ID J:119477)
  • partial embryonic lethality during organogenesis
    • embryos are recovered at a lower frequency (15% vs expected 25%) at E13.5   (MGI Ref ID J:119477)
  • embryogenesis phenotype
  • *normal* embryogenesis phenotype
    • mutants show normal vascularization of the yolk sac and placental labyrinth   (MGI Ref ID J:119477)
    • abnormal embryonic erythropoiesis
      • fetal-derived hematopoietic progenitors form larger CFU-E (colony-forming unit-erythroid) and BFU-E (burst-forming unit-erythroid) colonies compared with controls   (MGI Ref ID J:119477)
      • abnormal embryonic erythrocyte morphology
        • red blood cells appear immature compared to wild-type and occasionally highly atypical, consisten with a block in erythroid differentiation   (MGI Ref ID J:119477)
  • cardiovascular system phenotype
  • abnormal atrioventricular valve morphology
    • atrioventricular valve malformations   (MGI Ref ID J:119477)
  • abnormal cardiovascular system physiology
    • heart defects lead to heart failure and death in embryos by ~E14.5   (MGI Ref ID J:119477)
    • hemorrhage
      • embryos appear normal at E12.5, but rapidly develop peripheral hemorrhages by E13.5, consistent with heart failure   (MGI Ref ID J:119477)
  • conotruncal ridge hyperplasia
    • excess cushion tissue often leads to obstructed outflow tract   (MGI Ref ID J:119477)
  • double outlet right ventricle
    • at E13.5, embryos frequently show double outlet right ventricle   (MGI Ref ID J:119477)
  • ventricular septal defect
    • all embryonic hearts have prominent septal defects   (MGI Ref ID J:119477)
  • hematopoietic system phenotype
  • abnormal embryonic erythropoiesis
    • fetal-derived hematopoietic progenitors form larger CFU-E (colony-forming unit-erythroid) and BFU-E (burst-forming unit-erythroid) colonies compared with controls   (MGI Ref ID J:119477)
    • abnormal embryonic erythrocyte morphology
      • red blood cells appear immature compared to wild-type and occasionally highly atypical, consisten with a block in erythroid differentiation   (MGI Ref ID J:119477)
  • respiratory system phenotype
  • abnormal branching involved in lung morphogenesis
    • defects in lung branching are apparent by E11.5 compared to controls in vivo and in cultured lungs   (MGI Ref ID J:119477)
    • decrease in branching is associated with formation of large, fluid-filled sacs rather than normal terminal branches   (MGI Ref ID J:119477)
    • impaired branching involved in bronchus morphogenesis
      • at E12.5, mutant lungs exhibit large dilated bronchi whereas wild-type lungs show secondary and tertiary bronchi   (MGI Ref ID J:119477)
      • at E14.5, mutants lungs display dilated bronchi and only a few terminal bronchi   (MGI Ref ID J:119477)
    • impaired branching involved in terminal bronchiole morphogenesis
      • at E14.5, mutants lungs display only a few terminal bronchioles   (MGI Ref ID J:119477)
  • abnormal bronchus morphology
    • at E12.5, lungs exhibit large dilated bronchi; defect is more pronounced at E14.5   (MGI Ref ID J:119477)
    • impaired branching involved in bronchus morphogenesis
      • at E12.5, mutant lungs exhibit large dilated bronchi whereas wild-type lungs show secondary and tertiary bronchi   (MGI Ref ID J:119477)
      • at E14.5, mutants lungs display dilated bronchi and only a few terminal bronchi   (MGI Ref ID J:119477)
  • dilated respiratory conducting tubes
    • at E12.5, lungs exhibit large dilated bronchi; defect is more pronounced at E14.5   (MGI Ref ID J:119477)
  • liver/biliary system phenotype
  • increased hepatocyte apoptosis
    • at E12.5 fetal livers show large areas of apoptosis   (MGI Ref ID J:119477)
  • liver hypoplasia
    • at E12.5, fetal livers appear hypocellular   (MGI Ref ID J:119477)
  • homeostasis/metabolism phenotype
  • edema
    • embryos appear normal at E12.5, but rapidly develop edema by E13.5, consistent with heart failure   (MGI Ref ID J:119477)
  • integument phenotype
  • pallor
    • embryos appear normal at E12.5, but rapidly develop pallor by E13.5, consistent with heart failure   (MGI Ref ID J:119477)
  • cellular phenotype
  • increased hepatocyte apoptosis
    • at E12.5 fetal livers show large areas of apoptosis   (MGI Ref ID J:119477)

Krastm4Tyj/Kras+ Shhtm2(cre/ERT2)Cjt/Shh+

        involves: 129S2/SvPas * 129S4/SvJae   (conditional)
  • integument phenotype
  • *normal* integument phenotype
    • no epidermal defects or tumor formation are observed with tamoxifen treatment at day 28 (during period of up to 4 months after cre induction) when hair follicles are in full anlagen   (MGI Ref ID J:172048)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Developmental Biology Research
Embryonic Lethality (Homozygous)

Research Tools
Cre-lox System
      loxP-flanked Sequences

Genes & Alleles

Gene & Allele Information provided by MGI

Allele Symbol Krastm4Tyj
Allele Name targeted mutation 4, Tyler Jacks
Allele Type Targeted (Conditional ready (e.g. floxed), No functional change)
Common Name(s) K-Ras(G12D)fl; K-RasG12D; K-rasLSL; KR; Kras2tm4Tyj; Kras2tm14Tyj; KrasG12D; KrasLSL-G12D; KrasLox; LSL-K-ras G12D; LSL-K-rasG12D; LSL-Kras G12D; LSL-KrasG12D; LSL-KrasG12D; caKRas;
Mutation Made ByDr. Tyler Jacks,   Massachusetts Institute of Technology
Strain of Origin129S4/SvJae
ES Cell Line Strain129
Gene Symbol and Name Kras, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
Chromosome 6
Gene Common Name(s) AI929937; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; K-ras; KI-RAS; KRAS1; KRAS2; Kirsten rat sarcoma oncogene 2, expressed; Kras-2; Kras2; NS; NS3; RASK2; expressed sequence AI929937;
General Note Phenotypic Similarity to Human Syndrome: Intrahepatic Cholangiocarcinoma (J:184949).

Phenotypic Similarity to Human Syndrome: Granulosa cell tumor (GCT) J:186144

Phenotypic Similarity to Human Syndrome: Granulosa cell tumor of the testis (GCTT) J:186144

Phenotypic Similarity to Human Syndrome: Squamous Cell Carcinoma J:203922 in double Kras and Smad4 mutants.

Phenotypic Similarity to Human Syndrome: Soft Tissue Sarcoma J:125101 in double Kras and Trp53 mutants and in double Kras and Cdkn2a mutants.

Phenotypic Similarity to Human Syndrome: Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma J:155389, J:204376 in double Kras and Trp53 mutants.

Molecular Note By homologous recombination in ES cells, the Kras2 locus was targeted with a cassette containing an oncogenic form of the KRAS2 protein in which the glycine at position 12 had been substituted with a an aspartic acid. A loxP flanked stop codon was included upstream of the inserted Kras2 sequence, such that the mutant transcript would be expressed only after cre-mediated recombination. [MGI Ref ID J:73445]


Genotyping Information

Genotyping Protocols



Krastm4Tyj, Separated PCR
Krastm4Tyj, Standard PCR

Helpful Links

Genotyping resources and troubleshooting


References provided by MGI

Selected Reference(s)

Jackson EL; Willis N; Mercer K; Bronson RT; Crowley D; Montoya R; Jacks T; Tuveson DA. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15(24):3243-8. [PubMed: 11751630]  [MGI Ref ID J:73445]

Additional References

Krastm4Tyj related

Abel TW; Clark C; Bierie B; Chytil A; Aakre M; Gorska A; Moses HL. 2009. GFAP-Cre-mediated activation of oncogenic K-ras results in expansion of the subventricular zone and infiltrating glioma. Mol Cancer Res 7(5):645-53. [PubMed: 19435821]  [MGI Ref ID J:205246]

Abrigo M; Alvarez R; Paparella ML; Calb DE; Bal de Kier Joffe E; Gutkind JS; Raimondi AR. 2014. Impairing squamous differentiation by Klf4 deletion is sufficient to initiate tongue carcinoma development upon K-Ras activation in mice. Carcinogenesis 35(3):662-9. [PubMed: 24148820]  [MGI Ref ID J:206523]

Acin S; Li Z; Mejia O; Roop DR; El-Naggar AK; Caulin C. 2011. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol 225(4):479-89. [PubMed: 21952947]  [MGI Ref ID J:177463]

Aguilera KY; Rivera LB; Hur H; Carbon JG; Toombs JE; Goldstein CD; Dellinger MT; Castrillon DH; Brekken RA. 2014. Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Cancer Res 74(4):1032-44. [PubMed: 24346431]  [MGI Ref ID J:208362]

Aguirre AJ; Bardeesy N; Sinha M; Lopez L; Tuveson DA; Horner J; Redston MS; DePinho RA. 2003. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17(24):3112-26. [PubMed: 14681207]  [MGI Ref ID J:87196]

Ahmad I; Singh LB; Foth M; Morris CA; Taketo MM; Wu XR; Leung HY; Sansom OJ; Iwata T. 2011. K-Ras and {beta}-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Dis Model Mech 4(4):548-55. [PubMed: 21504907]  [MGI Ref ID J:174242]

Ahn YH; Yang Y; Gibbons DL; Creighton CJ; Yang F; Wistuba II; Lin W; Thilaganathan N; Alvarez CA; Roybal J; Goldsmith EJ; Tournier C; Kurie JM. 2011. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor gamma2 expression. Mol Cell Biol 31(21):4270-85. [PubMed: 21896780]  [MGI Ref ID J:178325]

Aichler M; Seiler C; Tost M; Siveke J; Mazur PK; Da Silva-Buttkus P; Bartsch DK; Langer P; Chiblak S; Durr A; Hofler H; Kloppel G; Muller-Decker K; Brielmeier M; Esposito I. 2012. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J Pathol 226(5):723-34. [PubMed: 21984419]  [MGI Ref ID J:183335]

Al Saati T; Clerc P; Hanoun N; Peuget S; Lulka H; Gigoux V; Capilla F; Beluchon B; Couvelard A; Selves J; Buscail L; Carrier A; Dusetti N; Dufresne M. 2013. Oxidative stress induced by inactivation of TP53INP1 cooperates with KrasG12D to initiate and promote pancreatic carcinogenesis in the murine pancreas. Am J Pathol 182(6):1996-2004. [PubMed: 23578383]  [MGI Ref ID J:198521]

Andreadi C; Cheung LK; Giblett S; Patel B; Jin H; Mercer K; Kamata T; Lee P; Williams A; McMahon M; Marais R; Pritchard C. 2012. The intermediate-activity L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes Dev 26(17):1945-58. [PubMed: 22892241]  [MGI Ref ID J:187371]

Ardito CM; Gruner BM; Takeuchi KK; Lubeseder-Martellato C; Teichmann N; Mazur PK; Delgiorno KE; Carpenter ES; Halbrook CJ; Hall JC; Pal D; Briel T; Herner A; Trajkovic-Arsic M; Sipos B; Liou GY; Storz P; Murray NR; Threadgill DW; Sibilia M; Washington MK; Wilson CL; Schmid RM; Raines EW; Crawford HC; Siveke JT. 2012. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22(3):304-17. [PubMed: 22975374]  [MGI Ref ID J:190126]

Avila JL; Troutman S; Durham A; Kissil JL. 2012. Notch1 is not required for acinar-to-ductal metaplasia in a model of Kras-induced pancreatic ductal adenocarcinoma. PLoS One 7(12):e52133. [PubMed: 23284900]  [MGI Ref ID J:195622]

Aytes A; Mitrofanova A; Kinkade CW; Lefebvre C; Lei M; Phelan V; Lekaye HC; Koutcher JA; Cardiff RD; Califano A; Shen MM; Abate-Shen C. 2013. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc Natl Acad Sci U S A 110(37):E3506-15. [PubMed: 23918374]  [MGI Ref ID J:200917]

Badea CT; Athreya KK; Espinosa G; Clark D; Ghafoori AP; Li Y; Kirsch DG; Johnson GA; Annapragada A; Ghaghada KB. 2012. Computed tomography imaging of primary lung cancer in mice using a liposomal-iodinated contrast agent. PLoS One 7(4):e34496. [PubMed: 22485175]  [MGI Ref ID J:187115]

Baek ST; Tallquist MD. 2012. Nf1 limits epicardial derivative expansion by regulating epithelial to mesenchymal transition and proliferation. Development 139(11):2040-9. [PubMed: 22535408]  [MGI Ref ID J:183991]

Bai H; Li H; Zhang W; Matkowskyj KA; Liao J; Srivastava SK; Yang GY. 2011. Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre mice. Carcinogenesis 32(11):1689-96. [PubMed: 21859833]  [MGI Ref ID J:177398]

Bardeesy N; Aguirre AJ; Chu GC; Cheng KH; Lopez LV; Hezel AF; Feng B; Brennan C; Weissleder R; Mahmood U; Hanahan D; Redston MS; Chin L; Depinho RA. 2006. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 103(15):5947-52. [PubMed: 16585505]  [MGI Ref ID J:108298]

Bardeesy N; Cheng KH; Berger JH; Chu GC; Pahler J; Olson P; Hezel AF; Horner J; Lauwers GY; Hanahan D; DePinho RA. 2006. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20(22):3130-46. [PubMed: 17114584]  [MGI Ref ID J:116130]

Basseres DS; Ebbs A; Levantini E; Baldwin AS. 2010. Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res 70(9):3537-46. [PubMed: 20406971]  [MGI Ref ID J:159456]

Bayne LJ; Beatty GL; Jhala N; Clark CE; Rhim AD; Stanger BZ; Vonderheide RH. 2012. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21(6):822-35. [PubMed: 22698406]  [MGI Ref ID J:189283]

Beilke S; Oswald F; Genze F; Wirth T; Adler G; Wagner M. 2010. The zinc-finger protein KCMF1 is overexpressed during pancreatic cancer development and downregulation of KCMF1 inhibits pancreatic cancer development in mice. Oncogene 29(28):4058-67. [PubMed: 20473331]  [MGI Ref ID J:162125]

Bennecke M; Kriegl L; Bajbouj M; Retzlaff K; Robine S; Jung A; Arkan MC; Kirchner T; Greten FR. 2010. Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 18(2):135-46. [PubMed: 20708155]  [MGI Ref ID J:163673]

Besmer DM; Curry JM; Roy LD; Tinder TL; Sahraei M; Schettini J; Hwang SI; Lee YY; Gendler SJ; Mukherjee P. 2011. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res 71(13):4432-42. [PubMed: 21558393]  [MGI Ref ID J:173616]

Blum JM; Ano L; Li Z; Van Mater D; Bennett BD; Sachdeva M; Lagutina I; Zhang M; Mito JK; Dodd LG; Cardona DM; Dodd RD; Williams N; Ma Y; Lepper C; Linardic CM; Mukherjee S; Grosveld GC; Fan CM; Kirsch DG. 2013. Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells. Cell Rep 5(4):933-40. [PubMed: 24239359]  [MGI Ref ID J:205518]

Borczuk AC; Sole M; Lu P; Chen J; Wilgus ML; Friedman RA; Albelda SM; Powell CA. 2011. Progression of Human Bronchioloalveolar Carcinoma to Invasive Adenocarcinoma Is Modeled in a Transgenic Mouse Model of K-ras-Induced Lung Cancer by Loss of the TGF-beta Type II Receptor. Cancer Res 71(21):6665-75. [PubMed: 21911454]  [MGI Ref ID J:177379]

Bornstein S; White R; Malkoski S; Oka M; Han G; Cleaver T; Reh D; Andersen P; Gross N; Olson S; Deng C; Lu SL; Wang XJ. 2009. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest 119(11):3408-19. [PubMed: 19841536]  [MGI Ref ID J:154600]

Brady CA; Jiang D; Mello SS; Johnson TM; Jarvis LA; Kozak MM; Kenzelmann Broz D; Basak S; Park EJ; McLaughlin ME; Karnezis AN; Attardi LD. 2011. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145(4):571-83. [PubMed: 21565614]  [MGI Ref ID J:173395]

Braun BS; Archard JA; Van Ziffle JA; Tuveson DA; Jacks TE; Shannon K. 2006. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood 108(6):2041-4. [PubMed: 16720837]  [MGI Ref ID J:115071]

Braun BS; Tuveson DA; Kong N; Le DT; Kogan SC; Rozmus J; Le Beau MM; Jacks TE; Shannon KM. 2004. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A 101(2):597-602. [PubMed: 14699048]  [MGI Ref ID J:87429]

Budiu RA; Diaconu I; Chrissluis R; Dricu A; Edwards RP; Vlad AM. 2009. A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells. Dis Model Mech 2(11-12):593-603. [PubMed: 19841240]  [MGI Ref ID J:154046]

Byun AJ; Hung KE; Fleet JC; Bronson RT; Mason JB; Garcia PE; Crott JW. 2014. Colon-specific tumorigenesis in mice driven by Cre-mediated inactivation of Apc and activation of mutant Kras. Cancer Lett 347(2):191-5. [PubMed: 24632531]  [MGI Ref ID J:210824]

Cai H; Memarzadeh S; Stoyanova T; Beharry Z; Kraft AS; Witte ON. 2012. Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. Cancer Res 72(18):4672-81. [PubMed: 22805308]  [MGI Ref ID J:191340]

Cai Z; Feng GS; Zhang X. 2010. Temporal requirement of the protein TyrosinePhosphatase Shp2 in establishing the neuronal fatein early retinal development. J Neurosci 30(11):4110-9. [PubMed: 20237281]  [MGI Ref ID J:159104]

Cai Z; Tao C; Li H; Ladher R; Gotoh N; Feng GS; Wang F; Zhang X. 2013. Deficient FGF signaling causes optic nerve dysgenesis and ocular coloboma. Development 140(13):2711-23. [PubMed: 23720040]  [MGI Ref ID J:198655]

Calcagno SR; Li S; Colon M; Kreinest PA; Thompson EA; Fields AP; Murray NR. 2008. Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon. Int J Cancer 122(11):2462-70. [PubMed: 18271008]  [MGI Ref ID J:135568]

Caldwell ME; DeNicola GM; Martins CP; Jacobetz MA; Maitra A; Hruban RH; Tuveson DA. 2012. Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene 31(12):1599-608. [PubMed: 21860420]  [MGI Ref ID J:186145]

Carretero J; Shimamura T; Rikova K; Jackson AL; Wilkerson MD; Borgman CL; Buttarazzi MS; Sanofsky BA; McNamara KL; Brandstetter KA; Walton ZE; Gu TL; Silva JC; Crosby K; Shapiro GI; Maira SM; Ji H; Castrillon DH; Kim CF; Garcia-Echeverria C; Bardeesy N; Sharpless NE; Hayes ND; Kim WY; Engelman JA; Wong KK. 2010. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17(6):547-59. [PubMed: 20541700]  [MGI Ref ID J:160885]

Carriere C; Seeley ES; Goetze T; Longnecker DS; Korc M. 2007. The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci U S A 104(11):4437-42. [PubMed: 17360542]  [MGI Ref ID J:120054]

Carriere C; Young AL; Gunn JR; Longnecker DS; Korc M. 2011. Acute pancreatitis accelerates initiation and progression to pancreatic cancer in mice expressing oncogenic Kras in the nestin cell lineage. PLoS One 6(11):e27725. [PubMed: 22140463]  [MGI Ref ID J:181133]

Carriere C; Young AL; Gunn JR; Longnecker DS; Korc M. 2009. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem Biophys Res Commun 382(3):561-5. [PubMed: 19292977]  [MGI Ref ID J:147870]

Caulin C; Nguyen T; Lang GA; Goepfert TM; Brinkley BR; Cai WW; Lozano G; Roop DR. 2007. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 117(7):1893-901. [PubMed: 17607363]  [MGI Ref ID J:124222]

Caulin C; Nguyen T; Longley MA; Zhou Z; Wang XJ; Roop DR. 2004. Inducible activation of oncogenic K-ras results in tumor formation in the oral cavity. Cancer Res 64(15):5054-8. [PubMed: 15289303]  [MGI Ref ID J:91877]

Cellurale C; Girnius N; Jiang F; Cavanagh-Kyros J; Lu S; Garlick DS; Mercurio AM; Davis RJ. 2012. Role of JNK in mammary gland development and breast cancer. Cancer Res 72(2):472-81. [PubMed: 22127926]  [MGI Ref ID J:181146]

Cellurale C; Sabio G; Kennedy NJ; Das M; Barlow M; Sandy P; Jacks T; Davis RJ. 2011. Requirement of c-Jun NH2-Terminal Kinase for Ras-Initiated Tumor Formation. Mol Cell Biol 31(7):1565-76. [PubMed: 21282468]  [MGI Ref ID J:170101]

Chan G; Cheung LS; Yang W; Milyavsky M; Sanders AD; Gu S; Hong WX; Liu AX; Wang X; Barbara M; Sharma T; Gavin J; Kutok JL; Iscove NN; Shannon KM; Dick JE; Neel BG; Braun BS. 2011. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood 117(16):4253-61. [PubMed: 21398220]  [MGI Ref ID J:173832]

Chan IS; Guy CD; Chen Y; Lu J; Swiderska-Syn M; Michelotti GA; Karaca G; Xie G; Kruger L; Syn WK; Anderson BR; Pereira TA; Choi SS; Baldwin AS; Diehl AM. 2012. Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma. Cancer Res 72(24):6344-50. [PubMed: 23066040]  [MGI Ref ID J:193639]

Chan IT; Kutok JL; Williams IR; Cohen S; Kelly L; Shigematsu H; Johnson L; Akashi K; Tuveson DA; Jacks T; Gilliland DG. 2004. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 113(4):528-38. [PubMed: 14966562]  [MGI Ref ID J:88163]

Chan IT; Kutok JL; Williams IR; Cohen S; Moore S; Shigematsu H; Ley TJ; Akashi K; Le Beau MM; Gilliland DG. 2006. Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease. Blood 108(5):1708-15. [PubMed: 16675706]  [MGI Ref ID J:115068]

Chang DR; Martinez Alanis D; Miller RK; Ji H; Akiyama H; McCrea PD; Chen J. 2013. Lung epithelial branching program antagonizes alveolar differentiation. Proc Natl Acad Sci U S A 110(45):18042-51. [PubMed: 24058167]  [MGI Ref ID J:202949]

Chang SH; Mirabolfathinejad SG; Katta H; Cumpian AM; Gong L; Caetano MS; Moghaddam SJ; Dong C. 2014. T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci U S A 111(15):5664-9. [PubMed: 24706787]  [MGI Ref ID J:208877]

Charles RP; Iezza G; Amendola E; Dankort D; McMahon M. 2011. Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse. Cancer Res 71(11):3863-71. [PubMed: 21512141]  [MGI Ref ID J:172205]

Chen L; Park SM; Tumanov AV; Hau A; Sawada K; Feig C; Turner JR; Fu YX; Romero IL; Lengyel E; Peter ME. 2010. CD95 promotes tumour growth. Nature 465(7297):492-6. [PubMed: 20505730]  [MGI Ref ID J:161953]

Chen Z; Cheng K; Walton Z; Wang Y; Ebi H; Shimamura T; Liu Y; Tupper T; Ouyang J; Li J; Gao P; Woo MS; Xu C; Yanagita M; Altabef A; Wang S; Lee C; Nakada Y; Pena CG; Sun Y; Franchetti Y; Yao C; Saur A; Cameron MD; Nishino M; Hayes DN; Wilkerson MD; Roberts PJ; Lee CB; Bardeesy N; Butaney M; Chirieac LR; Costa DB; Jackman D; Sharpless NE; Castrillon DH; Demetri GD; Janne PA; Pandolfi PP; Cantley LC; Kung AL; Engelman JA; Wong KK. 2012. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483(7391):613-7. [PubMed: 22425996]  [MGI Ref ID J:182575]

Cheung AF; Dupage MJ; Dong HK; Chen J; Jacks T. 2008. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res 68(22):9459-68. [PubMed: 19010921]  [MGI Ref ID J:141383]

Chiang MY; Xu L; Shestova O; Histen G; L'heureux S; Romany C; Childs ME; Gimotty PA; Aster JC; Pear WS. 2008. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest 118(9):3181-94. [PubMed: 18677410]  [MGI Ref ID J:142160]

Chiao PJ; Ling J. 2011. Kras, Pten, NF-kappaB, and inflammation: dangerous liaisons. Cancer Discov 1(2):103-5. [PubMed: 22586351]  [MGI Ref ID J:193072]

Cho HC; Lai CY; Shao LE; Yu J. 2011. Identification of Tumorigenic Cells in KrasG12D-Induced Lung Adenocarcinoma. Cancer Res 71(23):7250-8. [PubMed: 22088965]  [MGI Ref ID J:178608]

Chugh R; Sangwan V; Patil SP; Dudeja V; Dawra RK; Banerjee S; Schumacher RJ; Blazar BR; Georg GI; Vickers SM; Saluja AK. 2012. A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med 4(156):156ra139. [PubMed: 23076356]  [MGI Ref ID J:189216]

Clark CE; Hingorani SR; Mick R; Combs C; Tuveson DA; Vonderheide RH. 2007. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67(19):9518-27. [PubMed: 17909062]  [MGI Ref ID J:125575]

Clark PE; Polosukhina D; Love H; Correa H; Coffin C; Perlman EJ; de Caestecker M; Moses HL; Zent R. 2011. beta-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors. Am J Pathol 179(6):3045-55. [PubMed: 21983638]  [MGI Ref ID J:180084]

Collins MA; Brisset JC; Zhang Y; Bednar F; Pierre J; Heist KA; Galban CJ; Galban S; di Magliano MP. 2012. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One 7(12):e49707. [PubMed: 23226501]  [MGI Ref ID J:195686]

Collisson EA; Trejo CL; Silva JM; Gu S; Korkola JE; Heiser LM; Charles RP; Rabinovich BA; Hann B; Dankort D; Spellman PT; Phillips WA; Gray JW; McMahon M. 2012. A central role for RAF-->MEK-->ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2(8):685-93. [PubMed: 22628411]  [MGI Ref ID J:193065]

Colvin EK; Susanto JM; Kench JG; Ong VN; Mawson A; Pinese M; Chang DK; Rooman I; O'Toole SA; Segara D; Musgrove EA; Sutherland RL; Apte MV; Scarlett CJ; Biankin AV. 2011. Retinoid signaling in pancreatic cancer, injury and regeneration. PLoS One 6(12):e29075. [PubMed: 22220202]  [MGI Ref ID J:182325]

Connolly MK; Mallen-St Clair J; Bedrosian AS; Malhotra A; Vera V; Ibrahim J; Henning J; Pachter HL; Bar-Sagi D; Frey AB; Miller G. 2010. Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor. J Leukoc Biol 87(4):713-25. [PubMed: 20042467]  [MGI Ref ID J:158851]

Cook N; Frese KK; Bapiro TE; Jacobetz MA; Gopinathan A; Miller JL; Rao SS; Demuth T; Howat WJ; Jodrell DI; Tuveson DA. 2012. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med 209(3):437-44. [PubMed: 22351932]  [MGI Ref ID J:182504]

Corcoran RB; Cheng KA; Hata AN; Faber AC; Ebi H; Coffee EM; Greninger P; Brown RD; Godfrey JT; Cohoon TJ; Song Y; Lifshits E; Hung KE; Shioda T; Dias-Santagata D; Singh A; Settleman J; Benes CH; Mino-Kenudson M; Wong KK; Engelman JA. 2013. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23(1):121-8. [PubMed: 23245996]  [MGI Ref ID J:194363]

Corcoran RB; Contino G; Deshpande V; Tzatsos A; Conrad C; Benes CH; Levy DE; Settleman J; Engelman JA; Bardeesy N. 2011. STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis. Cancer Res 71(14):5020-9. [PubMed: 21586612]  [MGI Ref ID J:174088]

Cortez-Retamozo V; Etzrodt M; Newton A; Rauch PJ; Chudnovskiy A; Berger C; Ryan RJ; Iwamoto Y; Marinelli B; Gorbatov R; Forghani R; Novobrantseva TI; Koteliansky V; Figueiredo JL; Chen JW; Anderson DG; Nahrendorf M; Swirski FK; Weissleder R; Pittet MJ. 2012. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A 109(7):2491-6. [PubMed: 22308361]  [MGI Ref ID J:182625]

Cortez-Retamozo V; Etzrodt M; Newton A; Ryan R; Pucci F; Sio SW; Kuswanto W; Rauch PJ; Chudnovskiy A; Iwamoto Y; Kohler R; Marinelli B; Gorbatov R; Wojtkiewicz G; Panizzi P; Mino-Kenudson M; Forghani R; Figueiredo JL; Chen JW; Xavier R; Swirski FK; Nahrendorf M; Weissleder R; Pittet MJ. 2013. Angiotensin II Drives the Production of Tumor-Promoting Macrophages. Immunity 38(2):296-308. [PubMed: 23333075]  [MGI Ref ID J:193393]

Court H; Amoyel M; Hackman M; Lee KE; Xu R; Miller G; Bar-Sagi D; Bach EA; Bergo MO; Philips MR. 2013. Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. J Clin Invest :. [PubMed: 24216479]  [MGI Ref ID J:204180]

Courtin A; Richards FM; Bapiro TE; Bramhall JL; Neesse A; Cook N; Krippendorff BF; Tuveson DA; Jodrell DI. 2013. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. PLoS One 8(6):e67330. [PubMed: 23840665]  [MGI Ref ID J:203716]

Curtis SJ; Sinkevicius KW; Li D; Lau AN; Roach RR; Zamponi R; Woolfenden AE; Kirsch DG; Wong KK; Kim CF. 2010. Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. Cell Stem Cell 7(1):127-33. [PubMed: 20621056]  [MGI Ref ID J:162238]

Cutts BA; Sjogren AK; Andersson KM; Wahlstrom AM; Karlsson C; Swolin B; Bergo MO. 2009. Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice. Blood 114(17):3629-32. [PubMed: 19710506]  [MGI Ref ID J:153839]

Daikoku T; Tranguch S; Trofimova IN; Dinulescu DM; Jacks T; Nikitin AY; Connolly DC; Dey SK. 2006. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 66(5):2527-31. [PubMed: 16510568]  [MGI Ref ID J:106703]

Dail M; Li Q; McDaniel A; Wong J; Akagi K; Huang B; Kang HC; Kogan SC; Shokat K; Wolff L; Braun BS; Shannon K. 2010. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A 107(11):5106-11. [PubMed: 20194733]  [MGI Ref ID J:158752]

Daniluk J; Liu Y; Deng D; Chu J; Huang H; Gaiser S; Cruz-Monserrate Z; Wang H; Ji B; Logsdon CD. 2012. An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 122(4):1519-28. [PubMed: 22406536]  [MGI Ref ID J:184556]

Dasgupta B; Li W; Perry A; Gutmann DH. 2005. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res 65(1):236-45. [PubMed: 15665300]  [MGI Ref ID J:95509]

Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH. 2005. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 65(7):2755-60. [PubMed: 15805275]  [MGI Ref ID J:97360]

Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH. 2005. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma. Cancer Res 65(21):9843-50. [PubMed: 16267007]  [MGI Ref ID J:102692]

Davies CC; Chakraborty A; Cipriani F; Haigh K; Haigh JJ; Behrens A. 2010. Identification of a co-activator that links growth factor signalling to c-Jun/AP-1 activation. Nat Cell Biol 12(10):963-72. [PubMed: 20852630]  [MGI Ref ID J:173145]

De La O JP; Emerson LL; Goodman JL; Froebe SC; Illum BE; Curtis AB; Murtaugh LC. 2008. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A 105(48):18907-12. [PubMed: 19028876]  [MGI Ref ID J:142188]

De Raedt T; Walton Z; Yecies JL; Li D; Chen Y; Malone CF; Maertens O; Jeong SM; Bronson RT; Lebleu V; Kalluri R; Normant E; Haigis MC; Manning BD; Wong KK; Macleod KF; Cichowski K. 2011. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 20(3):400-13. [PubMed: 21907929]  [MGI Ref ID J:175966]

Desai TJ; Brownfield DG; Krasnow MA. 2014. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 507(7491):190-4. [PubMed: 24499815]  [MGI Ref ID J:207468]

Dineen SP; Roland CL; Greer R; Carbon JG; Toombs JE; Gupta P; Bardeesy N; Sun H; Williams N; Minna JD; Brekken RA. 2010. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 70(7):2852-61. [PubMed: 20332237]  [MGI Ref ID J:158892]

Dinulescu DM; Ince TA; Quade BJ; Shafer SA; Crowley D; Jacks T. 2005. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11(1):63-70. [PubMed: 15619626]  [MGI Ref ID J:96296]

Du J; Liu Y; Meline B; Kong G; Tan LX; Lo JC; Wang J; Ranheim E; Zhang L; Chang YI; Ryu MJ; Zhang JF; Zhang J. 2013. Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals. Leukemia 27(3):754-7. [PubMed: 22976127]  [MGI Ref ID J:196802]

DuPage M; Dooley AL; Jacks T. 2009. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4(7):1064-72. [PubMed: 19561589]  [MGI Ref ID J:201034]

DuPage M; Mazumdar C; Schmidt LM; Cheung AF; Jacks T. 2012. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482(7385):405-9. [PubMed: 22318517]  [MGI Ref ID J:181323]

Dufresne M; Clerc P; Dieng M; Edir A; Couvelard A; Delisle MB; Fourmy D; Gigoux V. 2011. Id3 modulates cellular localization of bHLH Ptf1-p48 protein. Int J Cancer 129(2):295-306. [PubMed: 20830706]  [MGI Ref ID J:173813]

Dupage M; Cheung AF; Mazumdar C; Winslow MM; Bronson R; Schmidt LM; Crowley D; Chen J; Jacks T. 2011. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 19(1):72-85. [PubMed: 21251614]  [MGI Ref ID J:168066]

Eisinger-Mathason TS; Zhang M; Qiu Q; Skuli N; Nakazawa MS; Karakasheva T; Mucaj V; Shay JE; Stangenberg L; Sadri N; Pure E; Yoon SS; Kirsch DG; Simon MC. 2013. Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov 3(10):1190-205. [PubMed: 23906982]  [MGI Ref ID J:204376]

Engelman JA; Chen L; Tan X; Crosby K; Guimaraes AR; Upadhyay R; Maira M; McNamara K; Perera SA; Song Y; Chirieac LR; Kaur R; Lightbown A; Simendinger J; Li T; Padera RF; Garcia-Echeverria C; Weissleder R; Mahmood U; Cantley LC; Wong KK. 2008. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14(12):1351-6. [PubMed: 19029981]  [MGI Ref ID J:142254]

Eser S; Messer M; Eser P; von Werder A; Seidler B; Bajbouj M; Vogelmann R; Meining A; von Burstin J; Algul H; Pagel P; Schnieke AE; Esposito I; Schmid RM; Schneider G; Saur D. 2011. In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging. Proc Natl Acad Sci U S A 108(24):9945-50. [PubMed: 21628592]  [MGI Ref ID J:173311]

Eser S; Reiff N; Messer M; Seidler B; Gottschalk K; Dobler M; Hieber M; Arbeiter A; Klein S; Kong B; Michalski CW; Schlitter AM; Esposito I; Kind AJ; Rad L; Schnieke AE; Baccarini M; Alessi DR; Rad R; Schmid RM; Schneider G; Saur D. 2013. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 23(3):406-20. [PubMed: 23453624]  [MGI Ref ID J:197054]

Esquela-Kerscher A; Trang P; Wiggins JF; Patrawala L; Cheng A; Ford L; Weidhaas JB; Brown D; Bader AG; Slack FJ. 2008. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7(6):759-64. [PubMed: 18344688]  [MGI Ref ID J:200138]

Faber AC; Coffee EM; Costa C; Dastur A; Ebi H; Hata AN; Yeo AT; Edelman EJ; Song Y; Tam AT; Boisvert JL; Milano RJ; Roper J; Kodack DP; Jain RK; Corcoran RB; Rivera MN; Ramaswamy S; Hung KE; Benes CH; Engelman JA. 2014. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov 4(1):42-52. [PubMed: 24163374]  [MGI Ref ID J:208914]

Faca VM; Song KS; Wang H; Zhang Q; Krasnoselsky AL; Newcomb LF; Plentz RR; Gurumurthy S; Redston MS; Pitteri SJ; Pereira-Faca SR; Ireton RC; Katayama H; Glukhova V; Phanstiel D; Brenner DE; Anderson MA; Misek D; Scholler N; Urban ND; Barnett MJ; Edelstein C; Goodman GE; Thornquist MD; McIntosh MW; DePinho RA; Bardeesy N; Hanash SM. 2008. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5(6):e123. [PubMed: 18547137]  [MGI Ref ID J:139894]

Fan HY; Liu Z; Paquet M; Wang J; Lydon JP; DeMayo FJ; Richards JS. 2009. Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. Cancer Res 69(16):6463-72. [PubMed: 19679546]  [MGI Ref ID J:151931]

Fan HY; Shimada M; Liu Z; Cahill N; Noma N; Wu Y; Gossen J; Richards JS. 2008. Selective expression of KrasG12D in granulosa cells of the mouse ovary causes defects in follicle development and ovulation. Development 135(12):2127-37. [PubMed: 18506027]  [MGI Ref ID J:137019]

Feig C; Jones JO; Kraman M; Wells RJ; Deonarine A; Chan DS; Connell CM; Roberts EW; Zhao Q; Caballero OL; Teichmann SA; Janowitz T; Jodrell DI; Tuveson DA; Fearon DT. 2013. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 110(50):20212-7. [PubMed: 24277834]  [MGI Ref ID J:205406]

Fendrich V; Schneider R; Maitra A; Jacobsen ID; Opfermann T; Bartsch DK. 2011. Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer. Neoplasia 13(2):180-6. [PubMed: 21403843]  [MGI Ref ID J:171634]

Feng Y; Sentani K; Wiese A; Sands E; Green M; Bommer GT; Cho KR; Fearon ER. 2013. Sox9 induction, ectopic paneth cells, and mitotic spindle axis defects in mouse colon adenomatous epithelium arising from conditional biallelic apc inactivation. Am J Pathol 183(2):493-503. [PubMed: 23769888]  [MGI Ref ID J:199069]

Frese KK; Neesse A; Cook N; Bapiro TE; Lolkema MP; Jodrell DI; Tuveson DA. 2012. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2(3):260-9. [PubMed: 22585996]  [MGI Ref ID J:193075]

Fukuda A; Wang SC; Morris JP 4th; Folias AE; Liou A; Kim GE; Akira S; Boucher KM; Firpo MA; Mulvihill SJ; Hebrok M. 2011. Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression. Cancer Cell 19(4):441-55. [PubMed: 21481787]  [MGI Ref ID J:170982]

Gades NM; Ohash A; Mills LD; Rowley MA; Predmore KS; Marler RJ; Couch FJ. 2008. Spontaneous vulvar papillomas in a colony of mice used for pancreatic cancer research. Comp Med 58(3):271-5. [PubMed: 18589869]  [MGI Ref ID J:140431]

Gao Q; Steine EJ; Barrasa MI; Hockemeyer D; Pawlak M; Fu D; Reddy S; Bell GW; Jaenisch R. 2011. Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression. Proc Natl Acad Sci U S A 108(44):18061-6. [PubMed: 22011581]  [MGI Ref ID J:180053]

Gao Y; Xiao Q; Ma H; Li L; Liu J; Feng Y; Fang Z; Wu J; Han X; Zhang J; Sun Y; Wu G; Padera R; Chen H; Wong KK; Ge G; Ji H. 2010. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci U S A 107(44):18892-7. [PubMed: 20956321]  [MGI Ref ID J:166159]

Gidekel Friedlander SY; Chu GC; Snyder EL; Girnius N; Dibelius G; Crowley D; Vasile E; DePinho RA; Jacks T. 2009. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 16(5):379-89. [PubMed: 19878870]  [MGI Ref ID J:153948]

Gier B; Matveyenko AV; Kirakossian D; Dawson D; Dry SM; Butler PC. 2012. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 61(5):1250-62. [PubMed: 22266668]  [MGI Ref ID J:196762]

Gilad O; Nabet BY; Ragland RL; Schoppy DW; Smith KD; Durham AC; Brown EJ. 2010. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res 70(23):9693-702. [PubMed: 21098704]  [MGI Ref ID J:166996]

Glasauer A; Sena LA; Diebold LP; Mazar AP; Chandel NS. 2014. Targeting SOD1 reduces experimental non-small-cell lung cancer. J Clin Invest 124(1):117-28. [PubMed: 24292713]  [MGI Ref ID J:207625]

Gorentla BK; Krishna S; Shin J; Inoue M; Shinohara ML; Grayson JM; Fukunaga R; Zhong XP. 2013. Mnk1 and 2 are dispensable for T cell development and activation but important for the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 190(3):1026-37. [PubMed: 23269249]  [MGI Ref ID J:193041]

Gregorian C; Nakashima J; Dry SM; Nghiemphu PL; Smith KB; Ao Y; Dang J; Lawson G; Mellinghoff IK; Mischel PS; Phelps M; Parada LF; Liu X; Sofroniew MV; Eilber FC; Wu H. 2009. PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A 106(46):19479-84. [PubMed: 19846776]  [MGI Ref ID J:154673]

Gritsman K; Yuzugullu H; Von T; Yan H; Clayton L; Fritsch C; Maira SM; Hollingworth G; Choi C; Khandan T; Paktinat M; Okabe RO; Roberts TM; Zhao JJ. 2014. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110alpha. J Clin Invest 124(4):1794-809. [PubMed: 24569456]  [MGI Ref ID J:209632]

Grivennikov SI; Wang K; Mucida D; Stewart CA; Schnabl B; Jauch D; Taniguchi K; Yu GY; Osterreicher CH; Hung KE; Datz C; Feng Y; Fearon ER; Oukka M; Tessarollo L; Coppola V; Yarovinsky F; Cheroutre H; Eckmann L; Trinchieri G; Karin M. 2012. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491(7423):254-8. [PubMed: 23034650]  [MGI Ref ID J:189226]

Gruner BM; Hahne H; Mazur PK; Trajkovic-Arsic M; Maier S; Esposito I; Kalideris E; Michalski CW; Kleeff J; Rauser S; Schmid RM; Kuster B; Walch A; Siveke JT. 2012. MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer. PLoS One 7(6):e39424. [PubMed: 22761793]  [MGI Ref ID J:187923]

Guo JY; Karsli-Uzunbas G; Mathew R; Aisner SC; Kamphorst JJ; Strohecker AM; Chen G; Price S; Lu W; Teng X; Snyder E; Santanam U; Dipaola RS; Jacks T; Rabinowitz JD; White E. 2013. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 27(13):1447-61. [PubMed: 23824538]  [MGI Ref ID J:199455]

Habbe N; Shi G; Meguid RA; Fendrich V; Esni F; Chen H; Feldmann G; Stoffers DA; Konieczny SF; Leach SD; Maitra A. 2008. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A 105(48):18913-8. [PubMed: 19028870]  [MGI Ref ID J:142189]

Hahnel PS; Enders B; Sasca D; Roos WP; Kaina B; Bullinger L; Theobald M; Kindler T. 2014. Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy. Blood 123(15):2355-66. [PubMed: 24505083]  [MGI Ref ID J:210173]

Haigis KM; Kendall KR; Wang Y; Cheung A; Haigis MC; Glickman JN; Niwa-Kawakita M; Sweet-Cordero A; Sebolt-Leopold J; Shannon KM; Settleman J; Giovannini M; Jacks T. 2008. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40(5):600-8. [PubMed: 18372904]  [MGI Ref ID J:132357]

Hamidi T; Algul H; Cano CE; Sandi MJ; Molejon MI; Riemann M; Calvo EL; Lomberk G; Dagorn JC; Weih F; Urrutia R; Schmid RM; Iovanna JL. 2012. Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis. J Clin Invest 122(6):2092-103. [PubMed: 22565310]  [MGI Ref ID J:188293]

Hammoud Z; Tan B; Badve S; Bigsby RM. 2008. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer 15(2):475-83. [PubMed: 18509000]  [MGI Ref ID J:149009]

Hanlon L; Avila JL; Demarest RM; Troutman S; Allen M; Ratti F; Rustgi AK; Stanger BZ; Radtke F; Adsay V; Long F; Capobianco AJ; Kissil JL. 2010. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res 70(11):4280-6. [PubMed: 20484026]  [MGI Ref ID J:160687]

Hegde GV; de la Cruz CC; Chiu C; Alag N; Schaefer G; Crocker L; Ross S; Goldenberg D; Merchant M; Tien J; Shao L; Roth L; Tsai SP; Stawicki S; Jin Z; Wyatt SK; Carano RA; Zheng Y; Sweet-Cordero EA; Wu Y; Jackson EL. 2013. Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci Transl Med 5(171):171ra18. [PubMed: 23390248]  [MGI Ref ID J:194531]

Hegedus B; Dasgupta B; Shin JE; Emnett RJ; Hart-Mahon EK; Elghazi L; Bernal-Mizrachi E; Gutmann DH. 2007. Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell 1(4):443-57. [PubMed: 18371380]  [MGI Ref ID J:139866]

Hegedus B; Yeh TH; Lee da Y; Emnett RJ; Li J; Gutmann DH. 2008. Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. Hum Mol Genet 17(19):2956-66. [PubMed: 18614544]  [MGI Ref ID J:138868]

Heidorn SJ; Milagre C; Whittaker S; Nourry A; Niculescu-Duvas I; Dhomen N; Hussain J; Reis-Filho JS; Springer CJ; Pritchard C; Marais R. 2010. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140(2):209-21. [PubMed: 20141835]  [MGI Ref ID J:161180]

Heiser PW; Cano DA; Landsman L; Kim GE; Kench JG; Klimstra DS; Taketo MM; Biankin AV; Hebrok M. 2008. Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology 135(4):1288-300. [PubMed: 18725219]  [MGI Ref ID J:142261]

Hezel AF; Deshpande V; Zimmerman SM; Contino G; Alagesan B; O'Dell MR; Rivera LB; Harper J; Lonning S; Brekken RA; Bardeesy N. 2012. TGF-beta and alphavbeta6 integrin act in a common pathway to suppress pancreatic cancer progression. Cancer Res 72(18):4840-5. [PubMed: 22787119]  [MGI Ref ID J:191017]

Hill R; Calvopina JH; Kim C; Wang Y; Dawson DW; Donahue TR; Dry S; Wu H. 2010. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res 70(18):7114-24. [PubMed: 20807812]  [MGI Ref ID J:164210]

Hill R; Li Y; Tran LM; Dry S; Calvopina JH; Garcia A; Kim C; Wang Y; Donahue TR; Herschman HR; Wu H. 2012. Cell intrinsic role of COX-2 in pancreatic cancer development. Mol Cancer Ther 11(10):2127-37. [PubMed: 22784710]  [MGI Ref ID J:208743]

Hingorani SR; Petricoin EF; Maitra A; Rajapakse V; King C; Jacobetz MA; Ross S; Conrads TP; Veenstra TD; Hitt BA; Kawaguchi Y; Johann D; Liotta LA; Crawford HC; Putt ME; Jacks T; Wright CV; Hruban RH; Lowy AM; Tuveson DA. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4(6):437-50. [PubMed: 14706336]  [MGI Ref ID J:87973]

Hingorani SR; Wang L; Multani AS; Combs C; Deramaudt TB; Hruban RH; Rustgi AK; Chang S; Tuveson DA. 2005. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7(5):469-83. [PubMed: 15894267]  [MGI Ref ID J:98936]

Ho VM; Schaffer BE; Karnezis AN; Park KS; Sage J. 2009. The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras. Oncogene 28(10):1393-9. [PubMed: 19151761]  [MGI Ref ID J:147590]

Hocker JR; Mohammed A; Aston CE; Brewer M; Lightfoot SA; Rao CV; Hanas JS. 2013. Mass profiling of serum to distinguish mice with pancreatic cancer induced by a transgenic Kras mutation. Int J Cancer 133(11):2662-71. [PubMed: 23712558]  [MGI Ref ID J:203351]

Horman SR; Velu CS; Chaubey A; Bourdeau T; Zhu J; Paul WE; Gebelein B; Grimes HL. 2009. Gfi1 integrates progenitor versus granulocytic transcriptional programming. Blood 113(22):5466-75. [PubMed: 19346496]  [MGI Ref ID J:148893]

Houghton AM; Rzymkiewicz DM; Ji H; Gregory AD; Egea EE; Metz HE; Stolz DB; Land SR; Marconcini LA; Kliment CR; Jenkins KM; Beaulieu KA; Mouded M; Frank SJ; Wong KK; Shapiro SD. 2010. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 16(2):219-23. [PubMed: 20081861]  [MGI Ref ID J:157079]

Hung KE; Maricevich MA; Richard LG; Chen WY; Richardson MP; Kunin A; Bronson RT; Mahmood U; Kucherlapati R. 2010. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci U S A :. [PubMed: 20080688]  [MGI Ref ID J:156532]

Ijichi H; Chytil A; Gorska AE; Aakre ME; Bierie B; Tada M; Mohri D; Miyabayashi K; Asaoka Y; Maeda S; Ikenoue T; Tateishi K; Wright CV; Koike K; Omata M; Moses HL. 2011. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest 121(10):4106-17. [PubMed: 21926469]  [MGI Ref ID J:178489]

Ijichi H; Chytil A; Gorska AE; Aakre ME; Fujitani Y; Fujitani S; Wright CV; Moses HL. 2006. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 20(22):3147-60. [PubMed: 17114585]  [MGI Ref ID J:116129]

Ischenko I; Petrenko O; Hayman MJ. 2014. Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas. Proc Natl Acad Sci U S A 111(9):3466-71. [PubMed: 24550494]  [MGI Ref ID J:207404]

Ischenko I; Zhi J; Moll UM; Nemajerova A; Petrenko O. 2013. Direct reprogramming by oncogenic Ras and Myc. Proc Natl Acad Sci U S A 110(10):3937-42. [PubMed: 23431158]  [MGI Ref ID J:196077]

Ittmann M; Huang J; Radaelli E; Martin P; Signoretti S; Sullivan R; Simons BW; Ward JM; Robinson BD; Chu GC; Loda M; Thomas G; Borowsky A; Cardiff RD. 2013. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 73(9):2718-36. [PubMed: 23610450]  [MGI Ref ID J:197036]

Iwanaga K; Yang Y; Raso MG; Ma L; Hanna AE; Thilaganathan N; Moghaddam S; Evans CM; Li H; Cai WW; Sato M; Minna JD; Wu H; Creighton CJ; Demayo FJ; Wistuba II; Kurie JM. 2008. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res 68(4):1119-27. [PubMed: 18281487]  [MGI Ref ID J:131721]

Izeradjene K; Combs C; Best M; Gopinathan A; Wagner A; Grady WM; Deng CX; Hruban RH; Adsay NV; Tuveson DA; Hingorani SR. 2007. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11(3):229-43. [PubMed: 17349581]  [MGI Ref ID J:119990]

Jackson EL; Olive KP; Tuveson DA; Bronson R; Crowley D; Brown M; Jacks T. 2005. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65(22):10280-8. [PubMed: 16288016]  [MGI Ref ID J:103407]

James MA; Vikis HG; Tate E; Rymaszewski AL; You M. 2014. CRR9/CLPTM1L regulates cell survival signaling and is required for Ras transformation and lung tumorigenesis. Cancer Res 74(4):1116-27. [PubMed: 24366883]  [MGI Ref ID J:208170]

Jamieson T; Clarke M; Steele CW; Samuel MS; Neumann J; Jung A; Huels D; Olson MF; Das S; Nibbs RJ; Sansom OJ. 2012. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest 122(9):3127-44. [PubMed: 22922255]  [MGI Ref ID J:190744]

Janzen DM; Rosales MA; Paik DY; Lee DS; Smith DA; Witte ON; Iruela-Arispe ML; Memarzadeh S. 2013. Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy. Cancer Res 73(15):4697-4710. [PubMed: 23744837]  [MGI Ref ID J:199569]

Ji H; Houghton AM; Mariani TJ; Perera S; Kim CB; Padera R; Tonon G; McNamara K; Marconcini LA; Hezel A; El-Bardeesy N; Bronson RT; Sugarbaker D; Maser RS; Shapiro SD; Wong KK. 2006. K-ras activation generates an inflammatory response in lung tumors. Oncogene 25(14):2105-12. [PubMed: 16288213]  [MGI Ref ID J:107260]

Ji H; Ramsey MR; Hayes DN; Fan C; McNamara K; Kozlowski P; Torrice C; Wu MC; Shimamura T; Perera SA; Liang MC; Cai D; Naumov GN; Bao L; Contreras CM; Li D; Chen L; Krishnamurthy J; Koivunen J; Chirieac LR; Padera RF; Bronson RT; Lindeman NI; Christiani DC; Lin X; Shapiro GI; Janne PA; Johnson BE; Meyerson M; Kwiatkowski DJ; Castrillon DH; Bardeesy N; Sharpless NE; Wong KK. 2007. LKB1 modulates lung cancer differentiation and metastasis. Nature 448(7155):807-10. [PubMed: 17676035]  [MGI Ref ID J:124682]

Jin Y; Li F; Zheng C; Wang Y; Fang Z; Guo C; Wang X; Liu H; Deng L; Li C; Wang H; Chen H; Feng Y; Ji H. 2014. NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition. Int J Cancer 134(10):2294-304. [PubMed: 24174333]  [MGI Ref ID J:211968]

Johnson L; Huseni M; Smyczek T; Lima A; Yeung S; Cheng JH; Molina R; Kan D; De Maziere A; Klumperman J; Kasman I; Zhang Y; Dennis MS; Eastham-Anderson J; Jubb AM; Hwang O; Desai R; Schmidt M; Nannini MA; Barck KH; Carano RA; Forrest WF; Song Q; Chen DS; Naumovski L; Singh M; Ye W; Hegde PS. 2013. Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J Clin Invest 123(9):3997-4009. [PubMed: 23945239]  [MGI Ref ID J:201596]

Juan J; Muraguchi T; Iezza G; Sears RC; McMahon M. 2014. Diminished WNT -> beta-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes Dev 28(6):561-75. [PubMed: 24589553]  [MGI Ref ID J:209631]

Jun S; Lee S; Kim HC; Ng C; Schneider AM; Ji H; Ying H; Wang H; DePinho RA; Park JI. 2013. PAF-mediated MAPK signaling hyperactivation via LAMTOR3 induces pancreatic tumorigenesis. Cell Rep 5(2):314-22. [PubMed: 24209743]  [MGI Ref ID J:205132]

Junttila MR; Karnezis AN; Garcia D; Madriles F; Kortlever RM; Rostker F; Brown Swigart L; Pham DM; Seo Y; Evan GI; Martins CP. 2010. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468(7323):567-71. [PubMed: 21107427]  [MGI Ref ID J:166973]

Kang R; Loux T; Tang D; Schapiro NE; Vernon P; Livesey KM; Krasinskas A; Lotze MT; Zeh HJ 3rd. 2012. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A 109(18):7031-6. [PubMed: 22509024]  [MGI Ref ID J:183916]

Kang TW; Yevsa T; Woller N; Hoenicke L; Wuestefeld T; Dauch D; Hohmeyer A; Gereke M; Rudalska R; Potapova A; Iken M; Vucur M; Weiss S; Heikenwalder M; Khan S; Gil J; Bruder D; Manns M; Schirmacher P; Tacke F; Ott M; Luedde T; Longerich T; Kubicka S; Zender L. 2011. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479(7374):547-51. [PubMed: 22080947]  [MGI Ref ID J:179823]

Karreth FA; Frese KK; DeNicola GM; Baccarini M; Tuveson DA. 2011. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov 1(2):128-36. [PubMed: 22043453]  [MGI Ref ID J:185634]

Kasinski AL; Slack FJ. 2012. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 72(21):5576-87. [PubMed: 22964582]  [MGI Ref ID J:191425]

Kelber JA; Reno T; Kaushal S; Metildi C; Wright T; Stoletov K; Weems JM; Park FD; Mose E; Wang Y; Hoffman RM; Lowy AM; Bouvet M; Klemke RL. 2012. KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. Cancer Res 72(10):2554-64. [PubMed: 22589274]  [MGI Ref ID J:189307]

Kelly-Spratt KS; Pitteri SJ; Gurley KE; Liggitt D; Chin A; Kennedy J; Wong CH; Zhang Q; Buson TB; Wang H; Hanash SM; Kemp CJ. 2011. Plasma proteome profiles associated with inflammation, angiogenesis, and cancer. PLoS One 6(5):e19721. [PubMed: 21589862]  [MGI Ref ID J:172643]

Kent OA; Chivukula RR; Mullendore M; Wentzel EA; Feldmann G; Lee KH; Liu S; Leach SD; Maitra A; Mendell JT. 2010. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev 24(24):2754-9. [PubMed: 21159816]  [MGI Ref ID J:166737]

Khandanpour C; Krongold J; Schutte J; Bouwman F; Vassen L; Gaudreau MC; Chen R; Calero-Nieto FJ; Diamanti E; Hannah R; Meyer SE; Grimes HL; van der Reijden BA; Jansen JH; Patel CV; Peeters JK; Lowenberg B; Duhrsen U; Gottgens B; Moroy T. 2012. The human GFI136N variant induces epigenetic changes at the Hoxa9 locus and accelerates K-RAS driven myeloproliferative disorder in mice. Blood 120(19):4006-17. [PubMed: 22932805]  [MGI Ref ID J:192927]

Khasawneh J; Schulz MD; Walch A; Rozman J; Hrabe de Angelis M; Klingenspor M; Buck A; Schwaiger M; Saur D; Schmid RM; Kloppel G; Sipos B; Greten FR; Arkan MC. 2009. Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A 106(9):3354-9. [PubMed: 19208810]  [MGI Ref ID J:146442]

Kim CF; Jackson EL; Kirsch DG; Grimm J; Shaw AT; Lane K; Kissil J; Olive KP; Sweet-Cordero A; Weissleder R; Jacks T. 2005. Mouse models of human non-small-cell lung cancer: raising the bar. Cold Spring Harb Symp Quant Biol 70:241-50. [PubMed: 16869760]  [MGI Ref ID J:116813]

Kim CF; Jackson EL; Woolfenden AE; Lawrence S; Babar I; Vogel S; Crowley D; Bronson RT; Jacks T. 2005. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121(6):823-35. [PubMed: 15960971]  [MGI Ref ID J:188904]

Kim WY; Perera S; Zhou B; Carretero J; Yeh JJ; Heathcote SA; Jackson AL; Nikolinakos P; Ospina B; Naumov G; Brandstetter KA; Weigman VJ; Zaghlul S; Hayes DN; Padera RF; Heymach JV; Kung AL; Sharpless NE; Kaelin WG Jr; Wong KK. 2009. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest 119(8):2160-70. [PubMed: 19662677]  [MGI Ref ID J:152717]

Kindler T; Cornejo MG; Scholl C; Liu J; Leeman DS; Haydu JE; Frohling S; Lee BH; Gilliland DG. 2008. K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood 112(8):3373-82. [PubMed: 18663146]  [MGI Ref ID J:140221]

Kinross KM; Montgomery KG; Kleinschmidt M; Waring P; Ivetac I; Tikoo A; Saad M; Hare L; Roh V; Mantamadiotis T; Sheppard KE; Ryland GL; Campbell IG; Gorringe KL; Christensen JG; Cullinane C; Hicks RJ; Pearson RB; Johnstone RW; McArthur GA; Phillips WA. 2012. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 122(2):553-7. [PubMed: 22214849]  [MGI Ref ID J:184382]

Kirsch DG; Dinulescu DM; Miller JB; Grimm J; Santiago PM; Young NP; Nielsen GP; Quade BJ; Chaber CJ; Schultz CP; Takeuchi O; Bronson RT; Crowley D; Korsmeyer SJ; Yoon SS; Hornicek FJ; Weissleder R; Jacks T. 2007. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 13(8):992-7. [PubMed: 17676052]  [MGI Ref ID J:125101]

Kissil JL; Walmsley MJ; Hanlon L; Haigis KM; Bender Kim CF; Sweet-Cordero A; Eckman MS; Tuveson DA; Capobianco AJ; Tybulewicz VL; Jacks T. 2007. Requirement for Rac1 in a K-ras Induced Lung Cancer in the Mouse. Cancer Res 67(17):8089-94. [PubMed: 17804720]  [MGI Ref ID J:124883]

Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA. 2007. Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia. Cancer Res 67(17):8121-30. [PubMed: 17804724]  [MGI Ref ID J:124882]

Kopp JL; von Figura G; Mayes E; Liu FF; Dubois CL; Morris JP 4th; Pan FC; Akiyama H; Wright CV; Jensen K; Hebrok M; Sander M. 2012. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22(6):737-50. [PubMed: 23201164]  [MGI Ref ID J:194378]

Kumar MS; Hancock DC; Molina-Arcas M; Steckel M; East P; Diefenbacher M; Armenteros-Monterroso E; Lassailly F; Matthews N; Nye E; Stamp G; Behrens A; Downward J. 2012. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149(3):642-55. [PubMed: 22541434]  [MGI Ref ID J:186195]

Kumar MS; Lu J; Mercer KL; Golub TR; Jacks T. 2007. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39(5):673-7. [PubMed: 17401365]  [MGI Ref ID J:123829]

Kumar MS; Pester RE; Chen CY; Lane K; Chin C; Lu J; Kirsch DG; Golub TR; Jacks T. 2009. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev 23(23):2700-4. [PubMed: 19903759]  [MGI Ref ID J:154907]

Laconti JJ; Shivapurkar N; Preet A; Deslattes Mays A; Peran I; Kim SE; Marshall JL; Riegel AT; Wellstein A. 2011. Tissue and Serum microRNAs in the Kras Transgenic Animal Model and in Patients with Pancreatic Cancer. PLoS One 6(6):e20687. [PubMed: 21738581]  [MGI Ref ID J:174427]

Lampson BL; Kendall SD; Ancrile BB; Morrison MM; Shealy MJ; Barrientos KS; Crowe MS; Kashatus DF; White RR; Gurley SB; Cardona DM; Counter CM. 2012. Targeting eNOS in pancreatic cancer. Cancer Res 72(17):4472-82. [PubMed: 22738914]  [MGI Ref ID J:191028]

Lanza-Jacoby S; Yan G; Radice G; Lephong C; Baliff J; Hess R. 2013. Calorie restriction delays the progression of lesions to pancreatic cancer in the LSL-KrasG12D; Pdx-1/Cre mouse model of pancreatic cancer. Exp Biol Med (Maywood) :. [PubMed: 23828595]  [MGI Ref ID J:199230]

Lapouge G; Beck B; Nassar D; Dubois C; Dekoninck S; Blanpain C. 2012. Skin squamous cell carcinoma propagating cells increase with tumour progression and invasiveness. EMBO J 31(24):4563-75. [PubMed: 23188079]  [MGI Ref ID J:193125]

Lapouge G; Youssef KK; Vokaer B; Achouri Y; Michaux C; Sotiropoulou PA; Blanpain C. 2011. Identifying the cellular origin of squamous skin tumors. Proc Natl Acad Sci U S A 108(18):7431-6. [PubMed: 21502497]  [MGI Ref ID J:172048]

Lee JC; Shin J; Baek KH. 2013. Trisomy of the Dscr1 gene suppresses early progression of pancreatic intraepithelial neoplasia driven by oncogenic Kras. Biochem Biophys Res Commun 440(1):50-5. [PubMed: 24041692]  [MGI Ref ID J:211430]

Lee KE; Bar-Sagi D. 2010. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell 18(5):448-58. [PubMed: 21075310]  [MGI Ref ID J:166831]

Lee SH; Hao E; Kiselyuk A; Shapiro J; Shields DJ; Lowy A; Levine F; Itkin-Ansari P. 2011. The Id3/E47 axis mediates cell-cycle control in human pancreatic ducts and adenocarcinoma. Mol Cancer Res 9(6):782-90. [PubMed: 21498546]  [MGI Ref ID J:205226]

Lee YS; Lee JW; Jang JW; Chi XZ; Kim JH; Li YH; Kim MK; Kim DM; Choi BS; Kim EG; Chung JH; Lee OJ; Lee YM; Suh JW; Chuang LS; Ito Y; Bae SC. 2013. Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell 24(5):603-16. [PubMed: 24229708]  [MGI Ref ID J:206737]

Lee da Y; Yeh TH; Emnett RJ; White CR; Gutmann DH. 2010. Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. Genes Dev 24(20):2317-29. [PubMed: 20876733]  [MGI Ref ID J:164880]

Lesina M; Kurkowski MU; Ludes K; Rose-John S; Treiber M; Kloppel G; Yoshimura A; Reindl W; Sipos B; Akira S; Schmid RM; Algul H. 2011. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19(4):456-69. [PubMed: 21481788]  [MGI Ref ID J:170981]

Li CM; Chen G; Dayton TL; Kim-Kiselak C; Hoersch S; Whittaker CA; Bronson RT; Beer DG; Winslow MM; Jacks T. 2013. Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. Genes Dev 27(14):1557-67. [PubMed: 23873940]  [MGI Ref ID J:199363]

Li H; Tan M; Jia L; Wei D; Zhao Y; Chen G; Xu J; Zhao L; Thomas D; Beer DG; Sun Y. 2014. Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis. J Clin Invest 124(2):835-46. [PubMed: 24430184]  [MGI Ref ID J:207982]

Li H; Yang AL; Chung YT; Zhang W; Liao J; Yang GY. 2013. Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10). Carcinogenesis 34(9):2090-8. [PubMed: 23689354]  [MGI Ref ID J:200524]

Li L; Hanahan D. 2013. Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion. Cell 153(1):86-100. [PubMed: 23540692]  [MGI Ref ID J:197249]

Liang MC; Ma J; Chen L; Kozlowski P; Qin W; Li D; Goto J; Shimamura T; Hayes DN; Meyerson M; Kwiatkowski DJ; Wong KK. 2010. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene 29(11):1588-97. [PubMed: 19966866]  [MGI Ref ID J:160400]

Licciulli S; Avila JL; Hanlon L; Troutman S; Cesaroni M; Kota S; Keith B; Simon MC; Pure E; Radtke F; Capobianco AJ; Kissil JL. 2013. Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53. Cancer Res 73(19):5974-84. [PubMed: 23943799]  [MGI Ref ID J:202615]

Lin C; Song H; Huang C; Yao E; Gacayan R; Xu SM; Chuang PT. 2012. Alveolar type II cells possess the capability of initiating lung tumor development. PLoS One 7(12):e53817. [PubMed: 23285300]  [MGI Ref ID J:195738]

Liu M; Sjogren AK; Karlsson C; Ibrahim MX; Andersson KM; Olofsson FJ; Wahlstrom AM; Dalin M; Yu H; Chen Z; Yang SH; Young SG; Bergo MO. 2010. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer. Proc Natl Acad Sci U S A 107(14):6471-6. [PubMed: 20308544]  [MGI Ref ID J:158937]

Liu Q; Xu C; Kirubakaran S; Zhang X; Hur W; Liu Y; Kwiatkowski NP; Wang J; Westover KD; Gao P; Ercan D; Niepel M; Thoreen CC; Kang SA; Patricelli MP; Wang Y; Tupper T; Altabef A; Kawamura H; Held KD; Chou DM; Elledge SJ; Janne PA; Wong KK; Sabatini DM; Gray NS. 2013. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res 73(8):2574-86. [PubMed: 23436801]  [MGI Ref ID J:197061]

Liu Y; Marks K; Cowley GS; Carretero J; Liu Q; Nieland TJ; Xu C; Cohoon TJ; Gao P; Zhang Y; Chen Z; Altabef AB; Tchaicha JH; Wang X; Choe S; Driggers EM; Zhang J; Bailey ST; Sharpless NE; Hayes DN; Patel NM; Janne PA; Bardeesy N; Engelman JA; Manning BD;Shaw RJ; Asara JM; Scully R; Kimmelman A; Byers LA; Gibbons DL; Wistuba II; Heymach JV; Kwiatkowski DJ; Kim WY; Kung AL; Gray NS; Root DE; Cantley LC; Wong KK. 2013. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov 3(8):870-9. [PubMed: 23715154]  [MGI Ref ID J:203634]

Lo B; Strasser G; Sagolla M; Austin CD; Junttila M; Mellman I. 2012. Lkb1 regulates organogenesis and early oncogenesis along AMPK-dependent and -independent pathways. J Cell Biol 199(7):1117-30. [PubMed: 23266956]  [MGI Ref ID J:195229]

Lu SL; Herrington H; Reh D; Weber S; Bornstein S; Wang D; Li AG; Tang CF; Siddiqui Y; Nord J; Andersen P; Corless CL; Wang XJ. 2006. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 20(10):1331-42. [PubMed: 16702406]  [MGI Ref ID J:108711]

Lyubynska N; Gorman MF; Lauchle JO; Hong WX; Akutagawa JK; Shannon K; Braun BS. 2011. A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice. Sci Transl Med 3(76):76ra27. [PubMed: 21451123]  [MGI Ref ID J:170811]

Maier HJ; Wagner M; Schips TG; Salem HH; Baumann B; Wirth T. 2013. Requirement of NEMO/IKKgamma for effective expansion of KRAS-induced precancerous lesions in the pancreas. Oncogene 32(21):2690-5. [PubMed: 22751123]  [MGI Ref ID J:198022]

Majeti BK; Lee JH; Simmons BH; Shojaei F. 2013. VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma. BMC Cancer 13(1):213. [PubMed: 23627488]  [MGI Ref ID J:197029]

Mallen-St Clair J; Soydaner-Azeloglu R; Lee KE; Taylor L; Livanos A; Pylayeva-Gupta Y; Miller G; Margueron R; Reinberg D; Bar-Sagi D. 2012. EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev 26(5):439-44. [PubMed: 22391448]  [MGI Ref ID J:181616]

Maniati E; Bossard M; Cook N; Candido JB; Emami-Shahri N; Nedospasov SA; Balkwill FR; Tuveson DA; Hagemann T. 2011. Crosstalk between the canonical NF-kappaB and Notch signaling pathways inhibits Ppargamma expression and promotes pancreatic cancer progression in mice. J Clin Invest 121(12):4685-99. [PubMed: 22056382]  [MGI Ref ID J:184026]

Mann KM; Ward JM; Yew CC; Kovochich A; Dawson DW; Black MA; Brett BT; Sheetz TE; Dupuy AJ; Chang DK; Biankin AV; Waddell N; Kassahn KS; Grimmond SM; Rust AG; Adams DJ; Jenkins NA; Copeland NG. 2012. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A 109(16):5934-41. [PubMed: 22421440]  [MGI Ref ID J:183391]

Mazumdar J; Hickey MM; Pant DK; Durham AC; Sweet-Cordero A; Vachani A; Jacks T; Chodosh LA; Kissil JL; Simon MC; Keith B. 2010. HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A 107(32):14182-7. [PubMed: 20660313]  [MGI Ref ID J:163616]

Mazur PK; Einwachter H; Lee M; Sipos B; Nakhai H; Rad R; Zimber-Strobl U; Strobl LJ; Radtke F; Kloppel G; Schmid RM; Siveke JT. 2010. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 107(30):13438-43. [PubMed: 20624967]  [MGI Ref ID J:162569]

Mazur PK; Gruner BM; Nakhai H; Sipos B; Zimber-Strobl U; Strobl LJ; Radtke F; Schmid RM; Siveke JT. 2010. Identification of epidermal Pdx1 expression discloses different roles of Notch1 and Notch2 in murine Kras(G12D)-induced skin carcinogenesis in vivo. PLoS One 5(10):e13578. [PubMed: 21042537]  [MGI Ref ID J:166709]

McAllister F; Bailey JM; Alsina J; Nirschl CJ; Sharma R; Fan H; Rattigan Y; Roeser JC; Lankapalli RH; Zhang H; Jaffee EM; Drake CG; Housseau F; Maitra A; Kolls JK; Sears CL; Pardoll DM; Leach SD. 2014. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25(5):621-37. [PubMed: 24823639]  [MGI Ref ID J:210592]

Menon R; Zhang Q; Zhang Y; Fermin D; Bardeesy N; DePinho RA; Lu C; Hanash SM; Omenn GS; States DJ. 2009. Identification of novel alternative splice isoforms of circulating proteins in a mouse model of human pancreatic cancer. Cancer Res 69(1):300-9. [PubMed: 19118015]  [MGI Ref ID J:143028]

Meyer SE; Hasenstein JR; Baktula A; Velu CS; Xu Y; Wan H; Whitsett JA; Gilks CB; Grimes HL. 2010. Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival. Am J Pathol 177(3):1503-13. [PubMed: 20639455]  [MGI Ref ID J:163466]

Meylan E; Dooley AL; Feldser DM; Shen L; Turk E; Ouyang C; Jacks T. 2009. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462(7269):104-7. [PubMed: 19847165]  [MGI Ref ID J:154041]

Miller AJ; Dudley SD; Tsao JL; Shibata D; Liskay RM. 2008. Tractable Cre-lox system for stochastic alteration of genes in mice. Nat Methods 5(3):227-9. [PubMed: 18264106]  [MGI Ref ID J:204653]

Miller KA; Yeager N; Baker K; Liao XH; Refetoff S; Di Cristofano A. 2009. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res 69(8):3689-94. [PubMed: 19351816]  [MGI Ref ID J:147732]

Miller SJ; Joshi BP; Feng Y; Gaustad A; Fearon ER; Wang TD. 2011. In vivo fluorescence-based endoscopic detection of colon dysplasia in the mouse using a novel peptide probe. PLoS One 6(3):e17384. [PubMed: 21408169]  [MGI Ref ID J:171709]

Mills LD; Zhang Y; Marler RJ; Herreros-Villanueva M; Zhang L; Almada LL; Couch F; Wetmore C; Pasca di Magliano M; Fernandez-Zapico ME. 2013. Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation. J Biol Chem 288(17):11786-94. [PubMed: 23482563]  [MGI Ref ID J:198390]

Mito JK; Riedel RF; Dodd L; Lahat G; Lazar AJ; Dodd RD; Stangenberg L; Eward WC; Hornicek FJ; Yoon SS; Brigman BE; Jacks T; Lev D; Mukherjee S; Kirsch DG. 2009. Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One 4(11):e8075. [PubMed: 19956606]  [MGI Ref ID J:155389]

Miyabayashi K; Ijichi H; Mohri D; Tada M; Yamamoto K; Asaoka Y; Ikenoue T; Tateishi K; Nakai Y; Isayama H; Morishita Y; Omata M; Moses HL; Koike K. 2013. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer Res 73(7):2221-34. [PubMed: 23378339]  [MGI Ref ID J:196975]

Moghaddam SJ; Barta P; Mirabolfathinejad SG; Ammar-Aouchiche Z; Garza NT; Vo TT; Newman RA; Aggarwal BB; Evans CM; Tuvim MJ; Lotan R; Dickey BF. 2009. Curcumin inhibits COPD-like airway inflammation and lung cancer progression in mice. Carcinogenesis 30(11):1949-56. [PubMed: 19793800]  [MGI Ref ID J:154790]

Moghaddam SJ; Li H; Cho SN; Dishop MK; Wistuba II; Ji L; Kurie JM; Dickey BF; Demayo FJ. 2009. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol 40(4):443-53. [PubMed: 18927348]  [MGI Ref ID J:159271]

Mohammed A; Janakiram NB; Brewer M; Duff A; Lightfoot S; Brush RS; Anderson RE; Rao CV. 2012. Endogenous n-3 polyunsaturated fatty acids delay progression of pancreatic ductal adenocarcinoma in Fat-1-p48(Cre/+)-LSL-Kras(G12D/+) mice. Neoplasia 14(12):1249-59. [PubMed: 23308056]  [MGI Ref ID J:195077]

Mohammed A; Janakiram NB; Li Q; Madka V; Ely M; Lightfoot S; Crawford H; Steele VE; Rao CV. 2010. The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. Cancer Prev Res (Phila) 3(11):1417-26. [PubMed: 21084261]  [MGI Ref ID J:168599]

Mohammed A; Qian L; Janakiram NB; Lightfoot S; Steele VE; Rao CV. 2012. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48(Cre/+) LSL-Kras(G12D/+) mice. Int J Cancer 131(8):1951-62. [PubMed: 22287227]  [MGI Ref ID J:187865]

Molina-Arcas M; Hancock DC; Sheridan C; Kumar MS; Downward J. 2013. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov 3(5):548-63. [PubMed: 23454899]  [MGI Ref ID J:200122]

Monahan KB; Rozenberg GI; Krishnamurthy J; Johnson SM; Liu W; Bradford MK; Horner J; Depinho RA; Sharpless NE. 2010. Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene :. [PubMed: 20697345]  [MGI Ref ID J:164588]

Morandell S; Reinhardt HC; Cannell IG; Kim JS; Ruf DM; Mitra T; Couvillon AD; Jacks T; Yaffe MB. 2013. A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo. Cell Rep 5(4):868-77. [PubMed: 24239348]  [MGI Ref ID J:203686]

Morel AP; Hinkal GW; Thomas C; Fauvet F; Courtois-Cox S; Wierinckx A; Devouassoux-Shisheboran M; Treilleux I; Tissier A; Gras B; Pourchet J; Puisieux I; Browne GJ; Spicer DB; Lachuer J; Ansieau S; Puisieux A. 2012. EMT Inducers Catalyze Malignant Transformation of Mammary Epithelial Cells and Drive Tumorigenesis towards Claudin-Low Tumors in Transgenic Mice. PLoS Genet 8(5):e1002723. [PubMed: 22654675]  [MGI Ref ID J:185192]

Morris JP 4th; Cano DA; Sekine S; Wang SC; Hebrok M. 2010. beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J Clin Invest 120(2):508-20. [PubMed: 20071774]  [MGI Ref ID J:156681]

Morton JP; Timpson P; Karim SA; Ridgway RA; Athineos D; Doyle B; Jamieson NB; Oien KA; Lowy AM; Brunton VG; Frame MC; Evans TR; Sansom OJ. 2010. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 107(1):246-51. [PubMed: 20018721]  [MGI Ref ID J:156461]

Mukherjee P; Basu GD; Tinder TL; Subramani DB; Bradley JM; Arefayene M; Skaar T; De Petris G. 2009. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 182(1):216-24. [PubMed: 19109152]  [MGI Ref ID J:143039]

Mukhopadhyay A; Krishnaswami SR; Cowing-Zitron C; Hung NJ; Reilly-Rhoten H; Burns J; Yu BD. 2013. Negative regulation of Shh levels by Kras and Fgfr2 during hair follicle development. Dev Biol 373(2):373-82. [PubMed: 23123965]  [MGI Ref ID J:192269]

Mukhopadhyay A; Krishnaswami SR; Yu BD. 2011. Activated Kras alters epidermal homeostasis of mouse skin, resulting in redundant skin and defective hair cycling. J Invest Dermatol 131(2):311-9. [PubMed: 20944652]  [MGI Ref ID J:180850]

Mulholland DJ; Kobayashi N; Ruscetti M; Zhi A; Tran LM; Huang J; Gleave M; Wu H. 2012. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 72(7):1878-89. [PubMed: 22350410]  [MGI Ref ID J:184935]

Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS. 2011. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene 30(32):3522-36. [PubMed: 21423204]  [MGI Ref ID J:174632]

Mullany LK; Liu Z; King ER; Wong KK; Richards JS. 2012. Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival. Endocrinology 153(4):1638-48. [PubMed: 22396451]  [MGI Ref ID J:183892]

Mullany LK; Liu Z; Wong KK; Deneke V; Ren YA; Herron A; Richards JS. 2014. Tumor repressor protein 53 and steroid hormones provide a new paradigm for ovarian cancer metastases. Mol Endocrinol 28(1):127-37. [PubMed: 24264574]  [MGI Ref ID J:211895]

Mullins CD; Su MY; Hucthagowder V; Chu L; Lu L; Kulkarni S; Novack D; Vij R; Tomasson MH. 2013. Germinal center B-cells resist transformation by kras independently of tumor suppressor arf. PLoS One 8(6):e67941. [PubMed: 23825691]  [MGI Ref ID J:203738]

Murphy DJ; Junttila MR; Pouyet L; Karnezis A; Shchors K; Bui DA; Brown-Swigart L; Johnson L; Evan GI. 2008. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 14(6):447-57. [PubMed: 19061836]  [MGI Ref ID J:142030]

Nakada Y; Stewart TG; Pena CG; Zhang S; Zhao N; Bardeesy N; Sharpless NE; Wong KK; Hayes DN; Castrillon DH. 2013. The LKB1 tumor suppressor as a biomarker in mouse and human tissues. PLoS One 8(9):e73449. [PubMed: 24086281]  [MGI Ref ID J:207525]

Nakagawa H; Hikiba Y; Hirata Y; Font-Burgada J; Sakamoto K; Hayakawa Y; Taniguchi K; Umemura A; Kinoshita H; Sakitani K; Nishikawa Y; Hirano K; Ikenoue T; Ijichi H; Dhar D; Shibata W; Akanuma M; Koike K; Karin M; Maeda S. 2014. Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis. Proc Natl Acad Sci U S A 111(3):1090-5. [PubMed: 24395807]  [MGI Ref ID J:206505]

Neesse A; Frese KK; Bapiro TE; Nakagawa T; Sternlicht MD; Seeley TW; Pilarsky C; Jodrell DI; Spong SM; Tuveson DA. 2013. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A 110(30):12325-30. [PubMed: 23836645]  [MGI Ref ID J:198792]

Ng CE; Sinha A; Krivtsov A; Dias S; Chang J; Armstrong SA; Kalaitzidis D. 2014. KRas(G12D)-evoked leukemogenesis does not require beta-catenin. Leukemia 28(3):698-702. [PubMed: 24189294]  [MGI Ref ID J:206982]

Nobis M; McGhee EJ; Morton JP; Schwarz JP; Karim SA; Quinn J; Edward M; Campbell AD; McGarry LC; Evans TR; Brunton VG; Frame MC; Carragher NO; Wang Y; Sansom OJ; Timpson P; Anderson KI. 2013. Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer. Cancer Res 73(15):4674-4686. [PubMed: 23749641]  [MGI Ref ID J:199648]

Nolan-Stevaux O; Lau J; Truitt ML; Chu GC; Hebrok M; Fernandez-Zapico ME; Hanahan D. 2009. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 23(1):24-36. [PubMed: 19136624]  [MGI Ref ID J:143478]

Norris AM; Gore A; Balboni A; Young A; Longnecker DS; Korc M. 2013. AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia. Oncogene 32(33):3867-76. [PubMed: 22945649]  [MGI Ref ID J:199980]

O'Dell MR; Huang JL; Whitney-Miller CL; Deshpande V; Rothberg P; Grose V; Rossi RM; Zhu AX; Land H; Bardeesy N; Hezel AF. 2012. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res 72(6):1557-67. [PubMed: 22266220]  [MGI Ref ID J:184949]

Ochi A; Nguyen AH; Bedrosian AS; Mushlin HM; Zarbakhsh S; Barilla R; Zambirinis CP; Fallon NC; Rehman A; Pylayeva-Gupta Y; Badar S; Hajdu CH; Frey AB; Bar-Sagi D; Miller G. 2012. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med 209(9):1671-87. [PubMed: 22908323]  [MGI Ref ID J:191814]

Okada N; Lin CP; Ribeiro MC; Biton A; Lai G; He X; Bu P; Vogel H; Jablons DM; Keller AC; Wilkinson JE; He B; Speed TP; He L. 2014. A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev 28(5):438-50. [PubMed: 24532687]  [MGI Ref ID J:209143]

Okayama H; Saito M; Oue N; Weiss JM; Stauffer J; Takenoshita S; Wiltrout RH; Hussain SP; Harris CC. 2013. NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression. Int J Cancer 132(1):9-18. [PubMed: 22618808]  [MGI Ref ID J:191775]

Olive KP; Jacobetz MA; Davidson CJ; Gopinathan A; McIntyre D; Honess D; Madhu B; Goldgraben MA; Caldwell ME; Allard D; Frese KK; Denicola G; Feig C; Combs C; Winter SP; Ireland-Zecchini H; Reichelt S; Howat WJ; Chang A; Dhara M; Wang L; Ruckert F; Grutzmann R; Pilarsky C; Izeradjene K; Hingorani SR; Huang P; Davies SE; Plunkett W; Egorin M; Hruban RH; Whitebread N; McGovern K; Adams J; Iacobuzio-Donahue C; Griffiths J; Tuveson DA. 2009. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933):1457-61. [PubMed: 19460966]  [MGI Ref ID J:149213]

Oliver TG; Mercer KL; Sayles LC; Burke JR; Mendus D; Lovejoy KS; Cheng MH; Subramanian A; Mu D; Powers S; Crowley D; Bronson RT; Whittaker CA; Bhutkar A; Lippard SJ; Golub T; Thomale J; Jacks T; Sweet-Cordero EA. 2010. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 24(8):837-52. [PubMed: 20395368]  [MGI Ref ID J:159101]

Oliver TG; Meylan E; Chang GP; Xue W; Burke JR; Humpton TJ; Hubbard D; Bhutkar A; Jacks T. 2011. Caspase-2-Mediated Cleavage of Mdm2 Creates a p53-Induced Positive Feedback Loop. Mol Cell 43(1):57-71. [PubMed: 21726810]  [MGI Ref ID J:174374]

Olson P; Chu GC; Perry SR; Nolan-Stevaux O; Hanahan D. 2011. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci U S A 108(49):E1275-84. [PubMed: 22084065]  [MGI Ref ID J:180399]

Osanyingbemi-Obidi J; Dobromilskaya I; Illei PB; Hann CL; Rudin CM. 2011. Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo. Mol Cancer Res 9(12):1746-54. [PubMed: 21994468]  [MGI Ref ID J:205398]

Pacheco-Pinedo EC; Durham AC; Stewart KM; Goss AM; Lu MM; Demayo FJ; Morrisey EE. 2011. Wnt/beta-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest 121(5):1935-45. [PubMed: 21490395]  [MGI Ref ID J:173950]

Page ME; Lombard P; Ng F; Gottgens B; Jensen KB. 2013. The epidermis comprises autonomous compartments maintained by distinct stem cell populations. Cell Stem Cell 13(4):471-82. [PubMed: 23954751]  [MGI Ref ID J:202041]

Palagani V; Bozko P; El Khatib M; Belahmer H; Giese N; Sipos B; Malek NP; Plentz RR. 2014. Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression. Carcinogenesis 35(4):859-66. [PubMed: 24293409]  [MGI Ref ID J:208182]

Pan Y; Carbe C; Powers A; Feng GS; Zhang X. 2010. Sprouty2-modulated Kras signaling rescues Shp2 deficiency during lens and lacrimal gland development. Development 137(7):1085-93. [PubMed: 20215346]  [MGI Ref ID J:158679]

Parikh N; Shuck RL; Nguyen TA; Herron A; Donehower LA. 2012. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses. Mol Cancer Res 10(6):845-55. [PubMed: 22532587]  [MGI Ref ID J:205390]

Park KS; Martelotto LG; Peifer M; Sos ML; Karnezis AN; Mahjoub MR; Bernard K; Conklin JF; Szczepny A; Yuan J; Guo R; Ospina B; Falzon J; Bennett S; Brown TJ; Markovic A; Devereux WL; Ocasio CA; Chen JK; Stearns T; Thomas RK; Dorsch M; Buonamici S; Watkins DN; Peacock CD; Sage J. 2011. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med 17(11):1504-8. [PubMed: 21983857]  [MGI Ref ID J:178123]

Pasca di Magliano M; Biankin AV; Heiser PW; Cano DA; Gutierrez PJ; Deramaudt T; Segara D; Dawson AC; Kench JG; Henshall SM; Sutherland RL; Dlugosz A; Rustgi AK; Hebrok M. 2007. Common activation of canonical wnt signaling in pancreatic adenocarcinoma. PLoS ONE 2(11):e1155. [PubMed: 17982507]  [MGI Ref ID J:130408]

Pasca di Magliano M; Sekine S; Ermilov A; Ferris J; Dlugosz AA; Hebrok M. 2006. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev 20(22):3161-73. [PubMed: 17114586]  [MGI Ref ID J:116111]

Patra KC; Wang Q; Bhaskar PT; Miller L; Wang Z; Wheaton W; Chandel N; Laakso M; Muller WJ; Allen EL; Jha AK; Smolen GA; Clasquin MF; Robey RB; Hay N. 2013. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24(2):213-28. [PubMed: 23911236]  [MGI Ref ID J:202526]

Pearson HB; Perez-Mancera PA; Dow LE; Ryan A; Tennstedt P; Bogani D; Elsum I; Greenfield A; Tuveson DA; Simon R; Humbert PO. 2011. SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J Clin Invest 121(11):4257-67. [PubMed: 21965329]  [MGI Ref ID J:178461]

Perera SA; Maser RS; Xia H; McNamara K; Protopopov A; Chen L; Hezel AF; Kim CF; Bronson RT; Castrillon DH; Chin L; Bardeesy N; Depinho RA; Wong KK. 2008. Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. Carcinogenesis 29(4):747-53. [PubMed: 18283039]  [MGI Ref ID J:133322]

Perez BA; Ghafoori AP; Lee CL; Johnston SM; Li Y; Moroshek JG; Ma Y; Mukherjee S; Kim Y; Badea CT; Kirsch DG. 2013. Assessing the radiation response of lung cancer with different gene mutations using genetically engineered mice. Front Oncol 3:72. [PubMed: 23565506]  [MGI Ref ID J:195492]

Perez-Mancera PA; Rust AG; van der Weyden L; Kristiansen G; Li A; Sarver AL; Silverstein KA; Grutzmann R; Aust D; Rummele P; Knosel T; Herd C; Stemple DL; Kettleborough R; Brosnan JA; Li A; Morgan R; Knight S; Yu J; Stegeman S; Collier LS; ten Hoeve JJ; de Ridder J; Klein AP; Goggins M; Hruban RH; Chang DK; Biankin AV; Grimmond SM; Wessels LF; Wood SA; Iacobuzio-Donahue CA; Pilarsky C; Largaespada DA; Adams DJ; Tuveson DA. 2012. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486(7402):266-70. [PubMed: 22699621]  [MGI Ref ID J:186717]

Peschard P; McCarthy A; Leblanc-Dominguez V; Yeo M; Guichard S; Stamp G; Marshall CJ. 2012. Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis. Curr Biol 22(21):2063-8. [PubMed: 23063435]  [MGI Ref ID J:199742]

Premsrirut PK; Dow LE; Kim SY; Camiolo M; Malone CD; Miething C; Scuoppo C; Zuber J; Dickins RA; Kogan SC; Shroyer KR; Sordella R; Hannon GJ; Lowe SW. 2011. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 145(1):145-58. [PubMed: 21458673]  [MGI Ref ID J:171191]

Provenzano PP; Cuevas C; Chang AE; Goel VK; Von Hoff DD; Hingorani SR. 2012. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21(3):418-29. [PubMed: 22439937]  [MGI Ref ID J:189345]

Pylayeva-Gupta Y; Lee KE; Hajdu CH; Miller G; Bar-Sagi D. 2012. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21(6):836-47. [PubMed: 22698407]  [MGI Ref ID J:189282]

Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH. 2011. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget 2(11):862-73. [PubMed: 22113502]  [MGI Ref ID J:198619]

Qu X; Hertzler K; Pan Y; Grobe K; Robinson ML; Zhang X. 2011. Genetic epistasis between heparan sulfate and FGF-Ras signaling controls lens development. Dev Biol 355(1):12-20. [PubMed: 21536023]  [MGI Ref ID J:173640]

Qu X; Pan Y; Carbe C; Powers A; Grobe K; Zhang X. 2012. Glycosaminoglycan-dependent restriction of FGF diffusion is necessary for lacrimal gland development. Development 139(15):2730-9. [PubMed: 22745308]  [MGI Ref ID J:185652]

Raddatz G; Gao Q; Bender S; Jaenisch R; Lyko F. 2012. Dnmt3a protects active chromosome domains against cancer-associated hypomethylation. PLoS Genet 8(12):e1003146. [PubMed: 23284304]  [MGI Ref ID J:194932]

Raimondi AR; Molinolo A; Gutkind JS. 2009. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res 69(10):4159-66. [PubMed: 19435901]  [MGI Ref ID J:148476]

Rajurkar M; De Jesus-Monge WE; Driscoll DR; Appleman VA; Huang H; Cotton JL; Klimstra DS; Zhu LJ; Simin K; Xu L; McMahon AP; Lewis BC; Mao J. 2012. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc Natl Acad Sci U S A 109(17):E1038-47. [PubMed: 22493246]  [MGI Ref ID J:183841]

Ray KC; Bell KM; Yan J; Gu G; Chung CH; Washington MK; Means AL. 2011. Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. PLoS One 6(2):e16786. [PubMed: 21311774]  [MGI Ref ID J:170906]

Regala RP; Davis RK; Kunz A; Khoor A; Leitges M; Fields AP. 2009. Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis. Cancer Res 69(19):7603-11. [PubMed: 19738040]  [MGI Ref ID J:153508]

Reichert M; Takano S; von Burstin J; Kim SB; Lee JS; Ihida-Stansbury K; Hahn C; Heeg S; Schneider G; Rhim AD; Stanger BZ; Rustgi AK. 2013. The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis. Genes Dev 27(3):288-300. [PubMed: 23355395]  [MGI Ref ID J:193476]

Rhim AD; Mirek ET; Aiello NM; Maitra A; Bailey JM; McAllister F; Reichert M; Beatty GL; Rustgi AK; Vonderheide RH; Leach SD; Stanger BZ. 2012. EMT and dissemination precede pancreatic tumor formation. Cell 148(1-2):349-61. [PubMed: 22265420]  [MGI Ref ID J:181291]

Richards JS; Fan HY; Liu Z; Tsoi M; Lague MN; Boyer A; Boerboom D. 2012. Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis. Oncogene 31(12):1504-20. [PubMed: 21860425]  [MGI Ref ID J:186144]

Rodriguez E; Mannion L; D'Santos P; Griffiths M; Arends MJ; Brindle KM; Lyons SK. 2014. Versatile and enhanced tumour modelling in mice via somatic cell transduction. J Pathol 232(4):449-57. [PubMed: 24307564]  [MGI Ref ID J:208063]

Rosenfeldt MT; O'Prey J; Morton JP; Nixon C; MacKay G; Mrowinska A; Au A; Rai TS; Zheng L; Ridgway R; Adams PD; Anderson KI; Gottlieb E; Sansom OJ; Ryan KM. 2013. p53 status determines the role of autophagy in pancreatic tumour development. Nature 504(7479):296-300. [PubMed: 24305049]  [MGI Ref ID J:207920]

Ryu MJ; Liu Y; Zhong X; Du J; Peterson N; Kong G; Li H; Wang J; Salamat S; Chang Q; Zhang J. 2012. Oncogenic Kras expression in postmitotic neurons leads to S100A8-S100A9 protein overexpression and gliosis. J Biol Chem 287(27):22948-58. [PubMed: 22577135]  [MGI Ref ID J:188377]

Sabbir MG; Prieditis H; Ravinsky E; Mowat MR. 2012. The role of Dlc1 isoform 2 in K-Ras2(G12D) induced thymic cancer. PLoS One 7(7):e40302. [PubMed: 22792269]  [MGI Ref ID J:189508]

Sabnis AJ; Cheung LS; Dail M; Kang HC; Santaguida M; Hermiston ML; Passegue E; Shannon K; Braun BS. 2009. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 7(3):e59. [PubMed: 19296721]  [MGI Ref ID J:149615]

Saborowski M; Saborowski A; Morris JP 4th; Bosbach B; Dow LE; Pelletier J; Klimstra DS; Lowe SW. 2014. A modular and flexible ESC-based mouse model of pancreatic cancer. Genes Dev 28(1):85-97. [PubMed: 24395249]  [MGI Ref ID J:205582]

Sahraei M; Roy LD; Curry JM; Teresa TL; Nath S; Besmer D; Kidiyoor A; Dalia R; Gendler SJ; Mukherjee P. 2012. MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene 31(47):4935-45. [PubMed: 22266848]  [MGI Ref ID J:191780]

Samuel MS; Lourenco FC; Olson MF. 2011. K-Ras mediated murine epidermal tumorigenesis is dependent upon and associated with elevated Rac1 activity. PLoS One 6(2):e17143. [PubMed: 21358804]  [MGI Ref ID J:171087]

Sankaran VG; Xu J; Ragoczy T; Ippolito GC; Walkley CR; Maika SD; Fujiwara Y; Ito M; Groudine M; Bender MA; Tucker PW; Orkin SH. 2009. Developmental and species-divergent globin switching are driven by BCL11A. Nature 460(7259):1093-7. [PubMed: 19657335]  [MGI Ref ID J:151995]

Santos AM; Jung J; Aziz N; Kissil JL; Pure E. 2009. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 119(12):3613-25. [PubMed: 19920354]  [MGI Ref ID J:155559]

Sasajima J; Mizukami Y; Sugiyama Y; Nakamura K; Kawamoto T; Koizumi K; Fujii R; Motomura W; Sato K; Suzuki Y; Tanno S; Fujiya M; Sasaki K; Shimizu N; Karasaki H; Kono T; Kawabe JI; Ii M; Yoshiara H; Kamiyama N; Ashida T; Bardeesy N; Chung DC; Kohgo Y. 2010. Transplanting Normal Vascular Proangiogenic Cells to Tumor-Bearing Mice Triggers Vascular Remodeling and Reduces Hypoxia in Tumors. Cancer Res 70(15):6283-6292. [PubMed: 20631070]  [MGI Ref ID J:162233]

Scarlett UK; Rutkowski MR; Rauwerdink AM; Fields J; Escovar-Fadul X; Baird J; Cubillos-Ruiz JR; Jacobs AC; Gonzalez JL; Weaver J; Fiering S; Conejo-Garcia JR. 2012. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 209(3):495-506. [PubMed: 22351930]  [MGI Ref ID J:182506]

Schepers AG; Snippert HJ; Stange DE; van den Born M; van Es JH; van de Wetering M; Clevers H. 2012. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337(6095):730-5. [PubMed: 22855427]  [MGI Ref ID J:186630]

Schmit F; Utermark T; Zhang S; Wang Q; Von T; Roberts TM; Zhao JJ. 2014. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A 111(17):6395-400. [PubMed: 24737887]  [MGI Ref ID J:208835]

Schramek D; Kotsinas A; Meixner A; Wada T; Elling U; Pospisilik JA; Neely GG; Zwick RH; Sigl V; Forni G; Serrano M; Gorgoulis VG; Penninger JM. 2011. The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nat Genet 43(3):212-9. [PubMed: 21317887]  [MGI Ref ID J:170904]

Schwitalla S; Fingerle AA; Cammareri P; Nebelsiek T; Goktuna SI; Ziegler PK; Canli O; Heijmans J; Huels DJ; Moreaux G; Rupec RA; Gerhard M; Schmid R; Barker N; Clevers H; Lang R; Neumann J; Kirchner T; Taketo MM; van den Brink GR; Sansom OJ; Arkan MC; Greten FR. 2013. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152(1-2):25-38. [PubMed: 23273993]  [MGI Ref ID J:197481]

Scotti ML; Smith KE; Butler AM; Calcagno SR; Crawford HC; Leitges M; Fields AP; Murray NR. 2012. Protein kinase C iota regulates pancreatic acinar-to-ductal metaplasia. PLoS One 7(2):e30509. [PubMed: 22359542]  [MGI Ref ID J:185224]

Seeley ES; Carriere C; Goetze T; Longnecker DS; Korc M. 2009. Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer Res 69(2):422-30. [PubMed: 19147554]  [MGI Ref ID J:143713]

Seidler B; Schmidt A; Mayr U; Nakhai H; Schmid RM; Schneider G; Saur D. 2008. A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors. Proc Natl Acad Sci U S A 105(29):10137-42. [PubMed: 18621715]  [MGI Ref ID J:140423]

Sengupta P; Basu S; Soni S; Pandey A; Roy B; Oh MS; Chin KT; Paraskar AS; Sarangi S; Connor Y; Sabbisetti VS; Kopparam J; Kulkarni A; Muto K; Amarasiriwardena C; Jayawardene I; Lupoli N; Dinulescu DM; Bonventre JV; Mashelkar RA; Sengupta S. 2012. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A 109(28):11294-9. [PubMed: 22733767]  [MGI Ref ID J:186400]

Seux M; Peuget S; Montero MP; Siret C; Rigot V; Clerc P; Gigoux V; Pellegrino E; Pouyet L; N'guessan P; Garcia S; Dufresne M; Iovanna JL; Carrier A; Andre F; Dusetti NJ. 2011. TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression. Oncogene 30(27):3049-61. [PubMed: 21339733]  [MGI Ref ID J:174642]

Shackelford DB; Abt E; Gerken L; Vasquez DS; Seki A; Leblanc M; Wei L; Fishbein MC; Czernin J; Mischel PS; Shaw RJ. 2013. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 23(2):143-58. [PubMed: 23352126]  [MGI Ref ID J:194330]

Shakya R; Gonda T; Quante M; Salas M; Kim S; Brooks J; Hirsch S; Davies J; Cullo A; Olive K; Wang TC; Szabolcs M; Tycko B; Ludwig T. 2013. Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma. Cancer Res 73(2):885-96. [PubMed: 23204224]  [MGI Ref ID J:194376]

Shakya R; Reid LJ; Reczek CR; Cole F; Egli D; Lin CS; deRooij DG; Hirsch S; Ravi K; Hicks JB; Szabolcs M; Jasin M; Baer R; Ludwig T. 2011. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science 334(6055):525-8. [PubMed: 22034435]  [MGI Ref ID J:177853]

Shankar S; Nall D; Tang SN; Meeker D; Passarini J; Sharma J; Srivastava RK. 2011. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 6(1):e16530. [PubMed: 21304978]  [MGI Ref ID J:169546]

Shaw AT; Meissner A; Dowdle JA; Crowley D; Magendantz M; Ouyang C; Parisi T; Rajagopal J; Blank LJ; Bronson RT; Stone JR; Tuveson DA; Jaenisch R; Jacks T. 2007. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev 21(6):694-707. [PubMed: 17369402]  [MGI Ref ID J:119477]

Shaw AT; Winslow MM; Magendantz M; Ouyang C; Dowdle J; Subramanian A; Lewis TA; Maglathin RL; Tolliday N; Jacks T. 2011. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A 108(21):8773-8. [PubMed: 21555567]  [MGI Ref ID J:171896]

Shen R; Wang Q; Cheng S; Liu T; Jiang H; Zhu J; Wu Y; Wang L. 2013. The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models. Cancer Lett 339(1):135-43. [PubMed: 23887057]  [MGI Ref ID J:202529]

Shi C; Washington MK; Chaturvedi R; Drosos Y; Revetta FL; Weaver CJ; Buzhardt E; Yull FE; Blackwell TS; Sosa-Pineda B; Whitehead RH; Beauchamp RD; Wilson KT; Means AL. 2014. Fibrogenesis in pancreatic cancer is a dynamic process regulated by macrophage-stellate cell interaction. Lab Invest 94(4):409-21. [PubMed: 24535260]  [MGI Ref ID J:208036]

Shi G; DiRenzo D; Qu C; Barney D; Miley D; Konieczny SF. 2013. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia. Oncogene 32(15):1950-8. [PubMed: 22665051]  [MGI Ref ID J:197233]

Shi G; Zhu L; Sun Y; Bettencourt R; Damsz B; Hruban RH; Konieczny SF. 2009. Loss of the acinar-restricted transcription factor Mist1 accelerates Kras-induced pancreatic intraepithelial neoplasia. Gastroenterology 136(4):1368-78. [PubMed: 19249398]  [MGI Ref ID J:148190]

Shields DJ; Murphy EA; Desgrosellier JS; Mielgo A; Lau SK; Barnes LA; Lesperance J; Huang M; Schmedt C; Tarin D; Lowy AM; Cheresh DA. 2011. Oncogenic Ras/Src cooperativity in pancreatic neoplasia. Oncogene 30(18):2123-34. [PubMed: 21242978]  [MGI Ref ID J:173715]

Shin J; Lee JC; Baek KH. 2014. A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis. Cancer Lett 342(1):70-81. [PubMed: 24051307]  [MGI Ref ID J:205062]

Simin K; Hill R; Song Y; Zhang Q; Bash R; Cardiff RD; Yin C; Xiao A; McCarthy K; van Dyke T. 2005. Deciphering cancer complexities in genetically engineered mice. Cold Spring Harb Symp Quant Biol 70:283-90. [PubMed: 16869764]  [MGI Ref ID J:116748]

Singh A; Greninger P; Rhodes D; Koopman L; Violette S; Bardeesy N; Settleman J. 2009. A gene expression signature associated with 'K-Ras addiction' reveals regulators of EMT and tumor cell survival. Cancer Cell 15(6):489-500. [PubMed: 19477428]  [MGI Ref ID J:149663]

Singh M; Couto SS; Forrest WF; Lima A; Cheng JH; Molina R; Long JE; Hamilton P; McNutt A; Kasman I; Nannini MA; Reslan HB; Cao TC; Ho CC; Barck KH; Carano RA; Foreman O; Eastham-Anderson J; Jubb AM; Ferrara N; Johnson L. 2012. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol 227(4):417-30. [PubMed: 22611036]  [MGI Ref ID J:187012]

Singh M; Lima A; Molina R; Hamilton P; Clermont AC; Devasthali V; Thompson JD; Cheng JH; Bou Reslan H; Ho CC; Cao TC; Lee CV; Nannini MA; Fuh G; Carano RA; Koeppen H; Yu RX; Forrest WF; Plowman GD; Johnson L. 2010. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 28(6):585-93. [PubMed: 20495549]  [MGI Ref ID J:208978]

Siveke JT; Einwachter H; Sipos B; Lubeseder-Martellato C; Kloppel G; Schmid RM. 2007. Concomitant Pancreatic Activation of Kras(G12D) and Tgfa Results in Cystic Papillary Neoplasms Reminiscent of Human IPMN. Cancer Cell 12(3):266-79. [PubMed: 17785207]  [MGI Ref ID J:124969]

Sjogren AK; Andersson KM; Khan O; Olofsson FJ; Karlsson C; Bergo MO. 2011. Inactivating GGTase-I reduces disease phenotypes in a mouse model of K-RAS-induced myeloproliferative disease. Leukemia 25(1):186-9. [PubMed: 20975663]  [MGI Ref ID J:167639]

Sjogren AK; Andersson KM; Liu M; Cutts BA; Karlsson C; Wahlstrom AM; Dalin M; Weinbaum C; Casey PJ; Tarkowski A; Swolin B; Young SG; Bergo MO. 2007. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest 117(5):1294-304. [PubMed: 17476360]  [MGI Ref ID J:122107]

Skoulidis F; Cassidy LD; Pisupati V; Jonasson JG; Bjarnason H; Eyfjord JE; Karreth FA; Lim M; Barber LM; Clatworthy SA; Davies SE; Olive KP; Tuveson DA; Venkitaraman AR. 2010. Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 18(5):499-509. [PubMed: 21056012]  [MGI Ref ID J:166678]

Smith C; Chang MY; Parker KH; Beury DW; DuHadaway JB; Flick HE; Boulden J; Sutanto-Ward E; Soler AP; Laury-Kleintop LD; Mandik-Nayak L; Metz R; Ostrand-Rosenberg S; Prendergast GC; Muller AJ. 2012. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2(8):722-35. [PubMed: 22822050]  [MGI Ref ID J:193156]

Snippert HJ; Schepers AG; van Es JH; Simons BD; Clevers H. 2014. Biased competition between Lgr5 intestinal stem cells driven by oncogenic mutation induces clonal expansion. EMBO Rep 15(1):62-9. [PubMed: 24355609]  [MGI Ref ID J:211965]

Snyder EL; Watanabe H; Magendantz M; Hoersch S; Chen TA; Wang DG; Crowley D; Whittaker CA; Meyerson M; Kimura S; Jacks T. 2013. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell 50(2):185-99. [PubMed: 23523371]  [MGI Ref ID J:198227]

Song Y; Zhang Q; Kutlu B; Difilippantonio S; Bash R; Gilbert D; Yin C; O'Sullivan TN; Yang C; Kozlov S; Bullitt E; McCarthy KD; Kafri T; Louis DN; Miller CR; Hood L; Van Dyke T. 2013. Evolutionary etiology of high-grade astrocytomas. Proc Natl Acad Sci U S A 110(44):17933-8. [PubMed: 24114272]  [MGI Ref ID J:201963]

Soucek L; Whitfield J; Martins CP; Finch AJ; Murphy DJ; Sodir NM; Karnezis AN; Swigart LB; Nasi S; Evan GI. 2008. Modelling Myc inhibition as a cancer therapy. Nature 455(7213):679-83. [PubMed: 18716624]  [MGI Ref ID J:141029]

Soucek L; Whitfield JR; Sodir NM; Masso-Valles D; Serrano E; Karnezis AN; Swigart LB; Evan GI. 2013. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 27(5):504-13. [PubMed: 23475959]  [MGI Ref ID J:212220]

Stopczynski RE; Normolle DP; Hartman DJ; Ying H; DeBerry JJ; Bielefeldt K; Rhim AD; DePinho RA; Albers KM; Davis BM. 2014. Neuroplastic changes occur early in the development of pancreatic ductal adenocarcinoma. Cancer Res 74(6):1718-27. [PubMed: 24448244]  [MGI Ref ID J:208150]

Su HT; Weng CC; Hsiao PJ; Chen LH; Kuo TL; Chen YW; Kuo KK; Cheng KH. 2013. Stem cell marker nestin is critical for TGF-beta1-mediated tumor progression in pancreatic cancer. Mol Cancer Res 11(7):768-79. [PubMed: 23552743]  [MGI Ref ID J:205461]

Su W; Xing R; Guha A; Gutmann DH; Sherman LS. 2007. Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging. Glia 55(7):723-33. [PubMed: 17348023]  [MGI Ref ID J:156097]

Sureban SM; May R; Lightfoot SA; Hoskins AB; Lerner M; Brackett DJ; Postier RG; Ramanujam R; Mohammed A; Rao CV; Wyche JH; Anant S; Houchen CW. 2011. DCAMKL-1 Regulates Epithelial-Mesenchymal Transition in Human Pancreatic Cells through a miR-200a-Dependent Mechanism. Cancer Res 71(6):2328-38. [PubMed: 21285251]  [MGI Ref ID J:170354]

Sutherland KD; Song JY; Kwon MC; Proost N; Zevenhoven J; Berns A. 2014. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc Natl Acad Sci U S A 111(13):4952-7. [PubMed: 24586047]  [MGI Ref ID J:207396]

Talluri S; Francis SM; Dick FA. 2013. Mutation of the LXCXE binding cleft of pRb facilitates transformation by ras in vitro but does not promote tumorigenesis in vivo. PLoS One 8(8):e72236. [PubMed: 23936539]  [MGI Ref ID J:205769]

Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK. 2013. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer. PLoS One 8(11):e80885. [PubMed: 24260500]  [MGI Ref ID J:206730]

Tang N; Marshall WF; McMahon M; Metzger RJ; Martin GR. 2011. Control of mitotic spindle angle by the RAS-regulated ERK1/2 pathway determines lung tube shape. Science 333(6040):342-5. [PubMed: 21764747]  [MGI Ref ID J:174194]

Tian H; Callahan CA; DuPree KJ; Darbonne WC; Ahn CP; Scales SJ; de Sauvage FJ. 2009. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A 106(11):4254-9. [PubMed: 19246386]  [MGI Ref ID J:146777]

Timpson P; McGhee EJ; Morton JP; von Kriegsheim A; Schwarz JP; Karim SA; Doyle B; Quinn JA; Carragher NO; Edward M; Olson MF; Frame MC; Brunton VG; Sansom OJ; Anderson KI. 2011. Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53. Cancer Res 71(3):747-57. [PubMed: 21266354]  [MGI Ref ID J:169401]

Tinder TL; Subramani DB; Basu GD; Bradley JM; Schettini J; Million A; Skaar T; Mukherjee P. 2008. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 181(5):3116-25. [PubMed: 18713982]  [MGI Ref ID J:138959]

Ting DT; Lipson D; Paul S; Brannigan BW; Akhavanfard S; Coffman EJ; Contino G; Deshpande V; Iafrate AJ; Letovsky S; Rivera MN; Bardeesy N; Maheswaran S; Haber DA. 2011. Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science 331(6017):593-6. [PubMed: 21233348]  [MGI Ref ID J:168148]

To MD; Rosario RD; Westcott PM; Banta KL; Balmain A. 2013. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis. Oncogene 32(34):4028-33. [PubMed: 22945650]  [MGI Ref ID J:203248]

Torchia EC; Caulin C; Acin S; Terzian T; Kubick BJ; Box NF; Roop DR. 2012. Myc, Aurora Kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma. Oncogene 31(21):2680-90. [PubMed: 21963848]  [MGI Ref ID J:186136]

Tran K; Risingsong R; Royce DB; Williams CR; Sporn MB; Pioli PA; Gediya LK; Njar VC; Liby KT. 2013. The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. Carcinogenesis 34(1):199-210. [PubMed: 23042302]  [MGI Ref ID J:193646]

Tran PT; Shroff EH; Burns TF; Thiyagarajan S; Das ST; Zabuawala T; Chen J; Cho YJ; Luong R; Tamayo P; Salih T; Aziz K; Adam SJ; Vicent S; Nielsen CH; Withofs N; Sweet-Cordero A; Gambhir SS; Rudin CM; Felsher DW. 2012. Twist1 suppresses senescence programs and thereby accelerates and maintains mutant kras-induced lung tumorigenesis. PLoS Genet 8(5):e1002650. [PubMed: 22654667]  [MGI Ref ID J:185196]

Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M. 2012. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer Res 72(12):3048-59. [PubMed: 22511580]  [MGI Ref ID J:189336]

Trobridge P; Knoblaugh S; Washington MK; Munoz NM; Tsuchiya KD; Rojas A; Song X; Ulrich CM; Sasazuki T; Shirasawa S; Grady WM. 2009. TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology 136(5):1680-8.e7. [PubMed: 19208363]  [MGI Ref ID J:148720]

Tuveson DA; Shaw AT; Willis NA; Silver DP; Jackson EL; Chang S; Mercer KL; Grochow R; Hock H; Crowley D; Hingorani SR; Zaks T; King C; Jacobetz MA; Wang L; Bronson RT; Orkin SH; DePinho RA; Jacks T. 2004. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5(4):375-87. [PubMed: 15093544]  [MGI Ref ID J:89333]

Tzatsos A; Paskaleva P; Ferrari F; Deshpande V; Stoykova S; Contino G; Wong KK; Lan F; Trojer P; Park PJ; Bardeesy N. 2013. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. J Clin Invest :. [PubMed: 23321669]  [MGI Ref ID J:194493]

Van Meter ME; Diaz-Flores E; Archard JA; Passegue E; Irish JM; Kotecha N; Nolan GP; Shannon K; Braun BS. 2007. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood 109(9):3945-52. [PubMed: 17192389]  [MGI Ref ID J:145335]

Vermeulen L; Morrissey E; van der Heijden M; Nicholson AM; Sottoriva A; Buczacki S; Kemp R; Tavare S; Winton DJ. 2013. Defining stem cell dynamics in models of intestinal tumor initiation. Science 342(6161):995-8. [PubMed: 24264992]  [MGI Ref ID J:205193]

Vernon PJ; Loux TJ; Schapiro NE; Kang R; Muthuswamy R; Kalinski P; Tang D; Lotze MT; Zeh HJ 3rd. 2013. The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. J Immunol 190(3):1372-9. [PubMed: 23269246]  [MGI Ref ID J:192593]

Vicent S; Chen R; Sayles LC; Lin C; Walker RG; Gillespie AK; Subramanian A; Hinkle G; Yang X; Saif S; Root DE; Huff V; Hahn WC; Sweet-Cordero EA. 2010. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest 120(11):3940-52. [PubMed: 20972333]  [MGI Ref ID J:167562]

Vincent DF; Gout J; Chuvin N; Arfi V; Pommier RM; Bertolino P; Jonckheere N; Ripoche D; Kaniewski B; Martel S; Langlois JB; Goddard-Leon S; Colombe A; Janier M; Van Seuningen I; Losson R; Valcourt U; Treilleux I; Dubus P; Bardeesy N; Bartholin L. 2012. Tif1gamma suppresses murine pancreatic tumoral transformation by a smad4-independent pathway. Am J Pathol 180(6):2214-21. [PubMed: 22469842]  [MGI Ref ID J:184706]

Vincent DF; Yan KP; Treilleux I; Gay F; Arfi V; Kaniewsky B; Marie JC; Lepinasse F; Martel S; Goddard-Leon S; Iovanna JL; Dubus P; Garcia S; Puisieux A; Rimokh R; Bardeesy N; Scoazec JY; Losson R; Bartholin L. 2009. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet 5(7):e1000575. [PubMed: 19629168]  [MGI Ref ID J:151781]

Wahlstrom AM; Cutts BA; Karlsson C; Andersson KM; Liu M; Sjogren AK; Swolin B; Young SG; Bergo MO. 2007. Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease. Blood 109(2):763-8. [PubMed: 16973961]  [MGI Ref ID J:143675]

Wahlstrom AM; Cutts BA; Liu M; Lindskog A; Karlsson C; Sjogren AK; Andersson KM; Young SG; Bergo MO. 2008. Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. Blood 112(4):1357-65. [PubMed: 18502828]  [MGI Ref ID J:138426]

Wang Z; Banerjee S; Ahmad A; Li Y; Azmi AS; Gunn JR; Kong D; Bao B; Ali S; Gao J; Mohammad RM; Miele L; Korc M; Sarkar FH. 2011. Activated K-ras and INK4a/Arf Deficiency Cooperate During the Development of Pancreatic Cancer by Activation of Notch and NF-kappaB Signaling Pathways. PLoS One 6(6):e20537. [PubMed: 21673986]  [MGI Ref ID J:174139]

Weinberg F; Hamanaka R; Wheaton WW; Weinberg S; Joseph J; Lopez M; Kalyanaraman B; Mutlu GM; Budinger GR; Chandel NS. 2010. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 107(19):8788-93. [PubMed: 20421486]  [MGI Ref ID J:160298]

Whipple CA; Young AL; Korc M. 2012. A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. Oncogene 31(20):2535-44. [PubMed: 21996748]  [MGI Ref ID J:186130]

White AC; Khuu JK; Dang CY; Hu J; Tran KV; Liu A; Gomez S; Zhang Z; Yi R; Scumpia P; Grigorian M; Lowry WE. 2014. Stem cell quiescence acts as a tumour suppressor in squamous tumours. Nat Cell Biol 16(1):99-107. [PubMed: 24335650]  [MGI Ref ID J:208368]

White AC; Tran K; Khuu J; Dang C; Cui Y; Binder SW; Lowry WE. 2011. Defining the origins of Ras/p53-mediated squamous cell carcinoma. Proc Natl Acad Sci U S A 108(18):7425-30. [PubMed: 21502519]  [MGI Ref ID J:172216]

White RA; Neiman JM; Reddi A; Han G; Birlea S; Mitra D; Dionne L; Fernandez P; Murao K; Bian L; Keysar SB; Goldstein NB; Song N; Bornstein S; Han Z; Lu X; Wisell J; Li F; Song J; Lu SL; Jimeno A; Roop DR; Wang XJ. 2013. Epithelial stem cell mutations that promote squamous cell carcinoma metastasis. J Clin Invest 123(10):4390-404. [PubMed: 23999427]  [MGI Ref ID J:203922]

Winslow MM; Dayton TL; Verhaak RG; Kim-Kiselak C; Snyder EL; Feldser DM; Hubbard DD; DuPage MJ; Whittaker CA; Hoersch S; Yoon S; Crowley D; Bronson RT; Chiang DY; Meyerson M; Jacks T. 2011. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473(7345):101-4. [PubMed: 21471965]  [MGI Ref ID J:171810]

Won JH; Zhang Y; Ji B; Logsdon CD; Yule DI. 2011. Phenotypic changes in mouse pancreatic stellate cell Ca2+ signaling events following activation in culture and in a disease model of pancreatitis. Mol Biol Cell 22(3):421-36. [PubMed: 21148289]  [MGI Ref ID J:182893]

Wong JC; Zhang Y; Lieuw KH; Tran MT; Forgo E; Weinfurtner K; Alzamora P; Kogan SC; Akagi K; Wolff L; Le Beau MM; Killeen N; Shannon K. 2010. Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies. Blood 115(22):4524-32. [PubMed: 20233966]  [MGI Ref ID J:161558]

Woolfenden S; Zhu H; Charest A. 2009. A Cre/LoxP conditional luciferase reporter transgenic mouse for bioluminescence monitoring of tumorigenesis. Genesis 47(10):659-666. [PubMed: 19603508]  [MGI Ref ID J:153565]

Xia Y; Yeddula N; Leblanc M; Ke E; Zhang Y; Oldfield E; Shaw RJ; Verma IM. 2012. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol 14(3):257-65. [PubMed: 22327365]  [MGI Ref ID J:185072]

Xiao Z; Jiang Q; Willette-Brown J; Xi S; Zhu F; Burkett S; Back T; Song NY; Datla M; Sun Z; Goldszmid R; Lin F; Cohoon T; Pike K; Wu X; Schrump DS; Wong KK; Young HA; Trinchieri G; Wiltrout RH; Hu Y. 2013. The pivotal role of IKKalpha in the development of spontaneous lung squamous cell carcinomas. Cancer Cell 23(4):527-40. [PubMed: 23597566]  [MGI Ref ID J:197037]

Xu X; Rock JR; Lu Y; Futtner C; Schwab B; Guinney J; Hogan BL; Onaitis MW. 2012. Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. Proc Natl Acad Sci U S A 109(13):4910-5. [PubMed: 22411819]  [MGI Ref ID J:182218]

Yang X; La Rosa FG; Genova EE; Huber K; Schaack J; Degregori J; Serkova NJ; Li Y; Su LJ; Kessler E; Flaig TW. 2013. Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia. PLoS One 8(9):e74809. [PubMed: 24058630]  [MGI Ref ID J:207342]

Yang Y; Iwanaga K; Raso MG; Wislez M; Hanna AE; Wieder ED; Molldrem JJ; Wistuba II; Powis G; Demayo FJ; Kim CF; Kurie JM. 2008. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS ONE 3(5):e2220. [PubMed: 18493606]  [MGI Ref ID J:136369]

Ying H; Elpek KG; Vinjamoori A; Zimmerman SM; Chu GC; Yan H; Fletcher-Sananikone E; Zhang H; Liu Y; Wang W; Ren X; Zheng H; Kimmelman AC; Paik JH; Lim C; Perry SR; Jiang S; Malinn B; Protopopov A; Colla S; Xiao Y; Hezel AF; Bardeesy N; Turley SJ; Wang YA; Chin L; Thayer SP; DePinho RA. 2011. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaB-cytokine network. Cancer Discov 1(2):158-69. [PubMed: 21984975]  [MGI Ref ID J:185636]

Young NP; Crowley D; Jacks T. 2011. Uncoupling Cancer Mutations Reveals Critical Timing of p53 Loss in Sarcomagenesis. Cancer Res 71(11):4040-7. [PubMed: 21512139]  [MGI Ref ID J:172206]

Zaslavsky A; Baek KH; Lynch RC; Short S; Grillo J; Folkman J; Italiano JE Jr; Ryeom S. 2010. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 115(22):4605-13. [PubMed: 20086246]  [MGI Ref ID J:161573]

Zhang J; Liu Y; Beard C; Tuveson DA; Jaenisch R; Jacks TE; Lodish HF. 2007. Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways. Blood 109(12):5238-41. [PubMed: 17317860]  [MGI Ref ID J:145429]

Zhang J; Wang J; Liu Y; Sidik H; Young KH; Lodish HF; Fleming MD. 2009. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood 113(6):1304-14. [PubMed: 19066392]  [MGI Ref ID J:145536]

Zhang N; Bai H; David KK; Dong J; Zheng Y; Cai J; Giovannini M; Liu P; Anders RA; Pan D. 2010. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 19(1):27-38. [PubMed: 20643348]  [MGI Ref ID J:162628]

Zhang Y; Morris JP 4th; Yan W; Schofield HK; Gurney A; Simeone DM; Millar SE; Hoey T; Hebrok M; Pasca di Magliano M. 2013. Canonical Wnt Signaling Is Required for Pancreatic Carcinogenesis. Cancer Res 73(15):4909-4922. [PubMed: 23761328]  [MGI Ref ID J:199468]

Zhang Y; Wong J; Klinger M; Tran MT; Shannon KM; Killeen N. 2009. MLL5 contributes to hematopoietic stem cell fitness and homeostasis. Blood 113(7):1455-63. [PubMed: 18818388]  [MGI Ref ID J:145449]

Zhang Y; Yan W; Collins MA; Bednar F; Rakshit S; Zetter BR; Stanger BZ; Chung I; Rhim AD; di Magliano MP. 2013. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res 73(20):6359-74. [PubMed: 24097820]  [MGI Ref ID J:205411]

Zhao P; Damerow MS; Stern P; Liu AH; Sweet-Cordero A; Siziopikou K; Neilson JR; Sharp PA; Cheng C. 2013. CD44 promotes Kras-dependent lung adenocarcinoma. Oncogene 32(43):5186-90. [PubMed: 23208496]  [MGI Ref ID J:203236]

Zhao Z; Zuber J; Diaz-Flores E; Lintault L; Kogan SC; Shannon K; Lowe SW. 2010. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 24(13):1389-402. [PubMed: 20595231]  [MGI Ref ID J:161357]

Zheng Y; Moore H; Piryatinska A; Solis T; Sweet-Cordero EA. 2013. Mathematical modeling of tumor cell proliferation kinetics and label retention in a mouse model of lung cancer. Cancer Res 73(12):3525-33. [PubMed: 23576555]  [MGI Ref ID J:198346]

Zheng Y; de la Cruz CC; Sayles LC; Alleyne-Chin C; Vaka D; Knaak TD; Bigos M; Xu Y; Hoang CD; Shrager JB; Fehling HJ; French D; Forrest W; Jiang Z; Carano RA; Barck KH; Jackson EL; Sweet-Cordero EA. 2013. A Rare Population of CD24(+)ITGB4(+)Notch(hi) Cells Drives Tumor Propagation in NSCLC and Requires Notch3 for Self-Renewal. Cancer Cell 24(1):59-74. [PubMed: 23845442]  [MGI Ref ID J:199306]

Zhou C; Licciulli S; Avila JL; Cho M; Troutman S; Jiang P; Kossenkov AV; Showe LC; Liu Q; Vachani A; Albelda SM; Kissil JL. 2012. The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis. Oncogene :. [PubMed: 22430205]  [MGI Ref ID J:187582]

Zhu L; Shi G; Schmidt CM; Hruban RH; Konieczny SF. 2007. Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol 171(1):263-73. [PubMed: 17591971]  [MGI Ref ID J:122825]

van der Weyden L; Alcolea MP; Jones PH; Rust AG; Arends MJ; Adams DJ. 2011. Acute sensitivity of the oral mucosa to oncogenic K-ras. J Pathol 224(1):22-32. [PubMed: 21381032]  [MGI Ref ID J:171248]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX10

Colony Maintenance

Breeding & HusbandryWhen maintained as a live colony, heterozygotes may be bred. Homozygotes are embryonic lethal.
Mating System+/+ sibling x Heterozygote         (Female x Male)   21-NOV-08
Diet Information LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls

Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $232.00Female or MaleHeterozygous for Krastm4Tyj  
Price per Pair (US dollars $)Pair Genotype
$304.00Heterozygous for Krastm4Tyj x Wild-type for Krastm4Tyj  
$304.00Wild-type for Krastm4Tyj x Heterozygous for Krastm4Tyj  

Standard Supply

Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $301.60Female or MaleHeterozygous for Krastm4Tyj  
Price per Pair (US dollars $)Pair Genotype
$395.20Heterozygous for Krastm4Tyj x Wild-type for Krastm4Tyj  
$395.20Wild-type for Krastm4Tyj x Heterozygous for Krastm4Tyj  

Standard Supply

Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Control Information

   Wild-type from the colony
   000664 C57BL/6J
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

See Terms of Use tab for General Terms and Conditions

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use

General Terms and Conditions

For Licensing and Use Restrictions view the link(s) below:
- Notice to customers in Canada.
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration


JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty


In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.